Scaling without slippage
Revenue up 10429.4% YoY while gross margin expanded +146181.5pp YoY to 71.3%
Frame pre-revenue biotech around cash runway, burn, and pipeline optionality instead of near-term profitability.
Pre-revenue biotech is not a margin story. It is a survival-and-optionality story shaped by cash runway, burn rate, R&D intensity, financing risk, and the value of future pipeline outcomes. The StatsAlpha(TM) biotech framework is designed to make that reality visible through runway-focused money flow, selective peer context, and a deliberately cautious analytical stance. It is for informational purposes only, not investment advice.
A quick read on where this framework looks strongest today.
Top slices selected from the strongest data already available for this industry.
Top 5 companies by current framework view
Recurring storylines, tone distribution, and representative beats pulled from active companies inside this setup.
Revenue up 10429.4% YoY while gross margin expanded +146181.5pp YoY to 71.3%
Revenue up 1273.2% YoY while gross margin expanded +14.8pp YoY to 83.6%
Revenue up 104.5% YoY while gross margin expanded +28.4pp YoY to 88.1%
For informational purposes only. Not investment advice.
Metrics that recur most often across stronger operators in this framework.
Pre-Revenue Biotech
This framework softens or disables Profitability in the Trade-Off Ledger lens.
Each axis sets a minimum evidence threshold. Higher coverage means the framework needs more supporting signals before the lens is treated as dependable.
Coverage thresholds and enabled metrics across the core trade-off axes.
Median and interquartile range across 1022 companies in this framework.
Interquartile ranges show where the middle half of companies cluster, with the median pin marking the center of gravity for each pillar.
Scan the full company universe mapped into the Biotech / Pre-Revenue framework using live search across company name, ticker, and industry.
| Company | Market Cap | Score | Price | Strongest Pillar |
|---|---|---|---|---|
|
Biotechnology
|
138.71B
|
66.4
Composite
|
$547.09
|
Profitability
84.9
|
|
MRNA
Moderna, Inc.
Biotechnology
|
101.48B
|
52.3
Composite
|
$254.19
|
Profitability
64.7
|
|
Biotechnology
|
93.55B
|
65.8
Composite
|
$904.35
|
Profitability
83.8
|
|
ARGX
argenx SE
Biotechnology
|
56.88B
|
67.5
Composite
|
$927.21
|
Profitability
87.1
|
|
ONC
BeiGene, Ltd.
Biotechnology
|
46.26B
|
70.8
Composite
|
$406.96
|
Profitability
83.9
|
|
Biotechnology
|
41.59B
|
55.8
Composite
|
$192.28
|
Profitability
69.5
|
|
GMAB
Genmab A/S
Biotechnology
|
33.47B
|
64.6
Composite
|
$53.63
|
Profitability
82.2
|
|
RPRX
Royalty Pharma plc
Biotechnology
|
30.09B
|
66.7
Composite
|
$67.30
|
Profitability
82.5
|
|
Biotechnology
|
28.08B
|
51.0
Composite
|
$38.88
|
Health
63.9
|
|
INSM
Insmed Incorporated
Biotechnology
|
25.10B
|
58.7
Composite
|
$114.41
|
Profitability
73.0
|
|
INCY
Incyte Corporation
Biotechnology
|
24.39B
|
66.9
Composite
|
$119.65
|
Profitability
86.0
|
|
Biotechnology
|
23.94B
|
65.3
Composite
|
$562.02
|
Profitability
84.6
|
|
BNTX
BioNTech SE
Biotechnology
|
21.70B
|
51.9
Composite
|
$87.51
|
Profitability
66.6
|
|
Biotechnology
|
20.89B
|
71.4
Composite
|
$155.94
|
Profitability
84.4
|
|
EXEL
Exelixis, Inc.
Biotechnology
|
16.98B
|
66.1
Composite
|
$69.57
|
Profitability
86.8
|
|
ASND
Ascendis Pharma A/S
Biotechnology
|
16.87B
|
72.5
Composite
|
$256.82
|
Profitability
84.3
|
|
Biotechnology
|
15.07B
|
72.4
Composite
|
$234.76
|
Profitability
81.4
|
|
Biotechnology
|
14.47B
|
56.2
Composite
|
$74.29
|
Profitability
72.0
|
|
Biotechnology
|
13.03B
|
52.2
Composite
|
$16.33
|
Growth
64.3
|
|
Biotechnology
|
11.76B
|
68.4
Composite
|
$103.63
|
Profitability
85.0
|
|
TECH
Bio-Techne Corp
Biotechnology
|
11.41B
|
72.4
Composite
|
$72.78
|
Profitability
83.4
|
|
Biotechnology
|
11.25B
|
59.4
Composite
|
$131.73
|
Profitability
79.3
|
|
Biotechnology
|
10.85B
|
66.2
Composite
|
$56.03
|
Profitability
81.6
|
|
PCVX
Vaxcyte, Inc.
Biotechnology
|
10.11B
|
51.7
Composite
|
$63.89
|
Profitability
61.1
|
|
Biotechnology
|
10.01B
|
61.3
Composite
|
$135.07
|
Profitability
70.3
|
|
Biotechnology
|
9.86B
|
60.8
Composite
|
$103.86
|
Profitability
69.8
|
|
NUVL
Nuvalent, Inc.
Biotechnology
|
9.82B
|
60.4
Composite
|
$123.96
|
Profitability
86.8
|
|
Biotechnology
|
9.28B
|
58.3
Composite
|
$399.63
|
Profitability
78.4
|
|
IBRX
ImmunityBio, Inc.
Biotechnology
|
9.15B
|
47.8
Composite
|
$8.63
|
Profitability
62.0
|
|
Biotechnology
|
8.92B
|
70.9
Composite
|
$300.88
|
Profitability
85.6
|
|
Biotechnology
|
8.87B
|
68.4
Composite
|
$59.83
|
Profitability
83.4
|
|
Biotechnology
|
8.82B
|
58.5
Composite
|
$84.95
|
Profitability
69.7
|
|
Biotechnology
|
8.54B
|
70.2
Composite
|
$132.04
|
Profitability
86.8
|
|
Biotechnology
|
8.22B
|
58.7
Composite
|
$58.16
|
Profitability
69.7
|
|
Biotechnology
|
7.96B
|
67.8
Composite
|
$72.77
|
Profitability
84.8
|
|
Biotechnology
|
7.78B
|
56.4
Composite
|
$112.28
|
Profitability
74.5
|
|
Biotechnology
|
7.75B
|
46.6
Composite
|
$277.62
|
Efficiency
57.4
|
|
ABVX
Abivax SA
Biotechnology
|
7.50B
|
46.7
Composite
|
$85.73
|
Health
47.8
|
|
Biotechnology
|
7.46B
|
47.9
Composite
|
$53.69
|
Profitability
63.8
|
|
MTSR
Metsera, Inc.
Biotechnology
|
7.43B
|
0.0
Composite
|
$70.50
|
No pillar score
-
|
|
Biotechnology
|
6.96B
|
58.7
Composite
|
$132.37
|
Profitability
72.1
|
|
ORKA
ARCA biopharma Inc
Biotechnology
|
6.81B
|
55.5
Composite
|
$102.86
|
Growth
68.6
|
|
ACLX
Arcellx, Inc.
Biotechnology
|
6.75B
|
51.6
Composite
|
$115.07
|
Profitability
60.2
|
|
CGON
CG Oncology, Inc.
Biotechnology
|
6.74B
|
54.0
Composite
|
$75.99
|
Efficiency
61.3
|
|
Biotechnology
|
6.55B
|
56.9
Composite
|
$39.42
|
Profitability
72.9
|
|
IMVT
Immunovant, Inc.
Biotechnology
|
6.31B
|
49.7
Composite
|
$30.53
|
Valuation
65.5
|
|
Biotechnology
|
6.27B
|
54.6
Composite
|
$40.50
|
Profitability
65.7
|
|
Biotechnology
|
6.23B
|
53.1
Composite
|
$99.30
|
Profitability
60.1
|
|
BLTE
Belite Bio, Inc
Biotechnology
|
6.21B
|
61.7
Composite
|
$154.19
|
Profitability
75.3
|
|
Biotechnology
|
6.12B
|
69.1
Composite
|
$306.20
|
Profitability
82.8
|
|
Biotechnology
|
6.12B
|
53.8
Composite
|
$93.72
|
Profitability
64.5
|
|
Biotechnology
|
6.11B
|
51.8
Composite
|
$52.95
|
Health
65.7
|
|
Biotechnology
|
5.72B
|
56.3
Composite
|
$46.94
|
Health
63.2
|
|
Biotechnology
|
5.49B
|
57.5
Composite
|
$31.64
|
Profitability
69.7
|
|
Biotechnology
|
5.47B
|
61.5
Composite
|
$65.44
|
Profitability
83.0
|
|
Biotechnology
|
5.25B
|
65.6
Composite
|
$41.03
|
Profitability
80.0
|
|
ERAS
Erasca, Inc.
Biotechnology
|
5.04B
|
57.2
Composite
|
$14.41
|
Profitability
69.0
|
|
Biotechnology
|
4.93B
|
54.1
Composite
|
$45.04
|
Profitability
65.5
|
|
Biotechnology
|
4.86B
|
53.0
Composite
|
$50.07
|
Profitability
63.0
|
|
Biotechnology
|
4.84B
|
58.0
Composite
|
$86.03
|
Growth
66.9
|
|
Biotechnology
|
4.76B
|
61.7
Composite
|
$49.60
|
Profitability
75.9
|
|
Biotechnology
|
4.55B
|
67.7
Composite
|
$14.49
|
Profitability
79.8
|
|
Biotechnology
|
4.53B
|
63.0
Composite
|
$23.40
|
Profitability
81.2
|
|
Biotechnology
|
4.53B
|
56.1
Composite
|
$27.98
|
Profitability
75.3
|
|
Biotechnology
|
4.11B
|
51.8
Composite
|
$18.60
|
Health
61.5
|
|
LQDA
Liquidia Corporation
Biotechnology
|
3.97B
|
79.2
Composite
|
$44.40
|
Profitability
88.9
|
|
Biotechnology
|
3.85B
|
65.4
Composite
|
$31.49
|
Profitability
85.3
|
|
Biotechnology
|
3.85B
|
58.6
Composite
|
$11.88
|
Efficiency
76.8
|
|
Biotechnology
|
3.79B
|
49.2
Composite
|
$39.17
|
Growth
58.4
|
|
Biotechnology
|
3.70B
|
54.5
Composite
|
$29.50
|
Profitability
71.7
|
|
Biotechnology
|
3.67B
|
65.0
Composite
|
$21.23
|
Profitability
84.4
|
|
Biotechnology
|
3.64B
|
60.9
Composite
|
$8.04
|
Profitability
75.1
|
|
Biotechnology
|
3.63B
|
60.1
Composite
|
$21.50
|
Profitability
76.6
|
|
Biotechnology
|
3.62B
|
56.0
Composite
|
$49.43
|
Health
63.6
|
|
IRON
Disc Medicine, Inc.
Biotechnology
|
3.50B
|
58.8
Composite
|
$78.91
|
Profitability
70.8
|
|
Biotechnology
|
3.42B
|
46.3
Composite
|
$26.84
|
Valuation
53.3
|
|
Biotechnology
|
3.38B
|
68.3
Composite
|
$68.60
|
Profitability
82.6
|
|
Biotechnology
|
3.37B
|
60.1
Composite
|
$18.07
|
Profitability
68.6
|
|
CELC
Celcuity Inc.
Biotechnology
|
3.27B
|
43.8
Composite
|
$66.79
|
Health
53.7
|
|
Biotechnology
|
3.24B
|
50.2
Composite
|
$28.49
|
Health
60.9
|
|
Biotechnology
|
3.23B
|
72.0
Composite
|
$25.55
|
Profitability
82.9
|
|
Biotechnology
|
3.22B
|
50.8
Composite
|
$20.07
|
Valuation
58.9
|
|
Biotechnology
|
3.19B
|
62.1
Composite
|
$9.63
|
Profitability
80.6
|
|
Biotechnology
|
3.02B
|
55.3
Composite
|
$31.24
|
Profitability
64.4
|
|
ZLAB
Zai Lab Limited
Biotechnology
|
2.86B
|
54.4
Composite
|
$25.48
|
Profitability
73.0
|
|
ADMA
ADMA Biologics Inc
Biotechnology
|
2.82B
|
63.5
Composite
|
$12.73
|
Profitability
81.7
|
|
VCEL
Vericel Corporation
Biotechnology
|
2.80B
|
68.9
Composite
|
$54.62
|
Profitability
82.4
|
|
Biotechnology
|
2.78B
|
61.3
Composite
|
$15.20
|
Profitability
78.7
|
|
Biotechnology
|
2.76B
|
68.2
Composite
|
$53.01
|
Profitability
86.7
|
|
XNCR
Xencor, Inc.
Biotechnology
|
2.68B
|
57.2
Composite
|
$35.75
|
Profitability
75.5
|
|
Biotechnology
|
2.63B
|
43.6
Composite
|
$26.41
|
Health
52.7
|
|
Biotechnology
|
2.63B
|
52.9
Composite
|
$18.28
|
Profitability
70.3
|
|
Biotechnology
|
2.53B
|
66.9
Composite
|
$175.92
|
Profitability
79.8
|
|
Biotechnology
|
2.47B
|
64.8
Composite
|
$51.35
|
Efficiency
87.2
|
|
PHVS
Pharvaris N.V.
Biotechnology
|
2.41B
|
60.4
Composite
|
$34.39
|
Profitability
72.3
|
|
Biotechnology
|
2.35B
|
49.6
Composite
|
$29.87
|
Health
60.4
|
|
SEPN
Septerna, Inc.
Biotechnology
|
2.28B
|
70.2
Composite
|
$48.85
|
Profitability
83.1
|
|
Biotechnology
|
2.27B
|
55.1
Composite
|
$18.90
|
Profitability
63.4
|
|
Biotechnology
|
2.22B
|
60.3
Composite
|
$21.53
|
Efficiency
73.9
|
|
IMNM
Immunome, Inc.
Biotechnology
|
2.21B
|
52.2
Composite
|
$18.71
|
Valuation
56.0
|
|
Biotechnology
|
2.21B
|
70.1
Composite
|
$16.46
|
Profitability
84.6
|
|
Biotechnology
|
2.19B
|
50.3
Composite
|
$3.52
|
Valuation
58.2
|
|
BHVN
Biohaven Ltd.
Biotechnology
|
2.19B
|
51.5
Composite
|
$14.48
|
Profitability
56.6
|
|
Biotechnology
|
2.15B
|
53.9
Composite
|
$29.79
|
Profitability
63.1
|
|
Biotechnology
|
2.12B
|
66.7
Composite
|
$21.96
|
Profitability
77.8
|
|
ZYME
Zymeworks Inc.
Biotechnology
|
2.10B
|
53.4
Composite
|
$29.63
|
Profitability
66.0
|
|
Biotechnology
|
2.09B
|
63.2
Composite
|
$12.21
|
Profitability
84.5
|
|
Biotechnology
|
2.05B
|
47.3
Composite
|
$21.62
|
Valuation
56.5
|
|
Biotechnology
|
2.04B
|
53.0
Composite
|
$14.33
|
Health
63.3
|
|
Biotechnology
|
1.98B
|
58.5
Composite
|
$7.69
|
Profitability
70.2
|
|
Biotechnology
|
1.96B
|
56.3
Composite
|
$7.29
|
Growth
70.0
|
|
Biotechnology
|
1.95B
|
66.3
Composite
|
$7.52
|
Profitability
78.3
|
|
GLPG
Galapagos NV
Biotechnology
|
1.95B
|
55.6
Composite
|
$29.60
|
Profitability
76.0
|
|
Biotechnology
|
1.94B
|
69.8
Composite
|
$33.11
|
Profitability
83.0
|
|
Biotechnology
|
1.91B
|
57.4
Composite
|
$17.82
|
Profitability
79.0
|
|
MESO
Mesoblast Limited
Biotechnology
|
1.85B
|
55.7
Composite
|
$14.27
|
Profitability
74.1
|
|
Biotechnology
|
1.84B
|
63.0
Composite
|
$34.19
|
Profitability
79.9
|
|
Biotechnology
|
1.84B
|
51.6
Composite
|
$28.26
|
Efficiency
67.1
|
|
Biotechnology
|
1.79B
|
58.4
Composite
|
$58.01
|
Profitability
65.1
|
|
NVAX
Novavax, Inc.
Biotechnology
|
1.78B
|
45.5
Composite
|
$10.78
|
Profitability
69.8
|
|
Biotechnology
|
1.76B
|
58.9
Composite
|
$29.41
|
Profitability
71.4
|
|
Biotechnology
|
1.75B
|
50.9
Composite
|
$18.09
|
Efficiency
85.4
|
|
ABSI
Absci Corporation
Biotechnology
|
1.75B
|
53.6
Composite
|
$10.17
|
Health
56.0
|
|
Biotechnology
|
1.74B
|
58.6
Composite
|
$26.54
|
Profitability
71.6
|
|
Biotechnology
|
1.70B
|
62.1
Composite
|
$8.42
|
Profitability
75.3
|
|
Biotechnology
|
1.67B
|
72.5
Composite
|
$15.30
|
Profitability
88.5
|
|
Shell Companies
|
1.67B
|
61.9
Composite
|
$18.83
|
Growth
87.5
|
|
PGEN
Precigen, Inc.
Biotechnology
|
1.60B
|
61.8
Composite
|
$4.47
|
Profitability
78.5
|
|
Biotechnology
|
1.60B
|
59.1
Composite
|
$30.99
|
Profitability
81.4
|
|
Biotechnology
|
1.59B
|
50.4
Composite
|
$11.35
|
Profitability
58.3
|
|
Biotechnology
|
1.57B
|
51.4
Composite
|
$15.43
|
Profitability
72.8
|
|
NBTX
Nanobiotix S.A.
Biotechnology
|
1.53B
|
51.6
Composite
|
$30.63
|
Profitability
65.2
|
|
QURE
uniQure N.V.
Biotechnology
|
1.52B
|
54.4
Composite
|
$21.70
|
Health
65.2
|
|
GLTO
Galecto, Inc.
Biotechnology
|
1.49B
|
51.8
Composite
|
$24.99
|
Profitability
65.7
|
|
NUVB
Nuvation Bio Inc.
Biotechnology
|
1.47B
|
61.3
Composite
|
$4.16
|
Profitability
72.7
|
|
Biotechnology
|
1.45B
|
52.9
Composite
|
$21.15
|
Valuation
63.9
|
|
Biotechnology
|
1.45B
|
56.7
Composite
|
$20.35
|
Profitability
58.9
|
|
Biotechnology
|
1.45B
|
63.1
Composite
|
$24.44
|
Profitability
79.4
|
|
Biotechnology
|
1.45B
|
55.8
Composite
|
$6.59
|
Profitability
68.7
|
|
Biotechnology
|
1.44B
|
58.1
Composite
|
$27.00
|
Profitability
71.5
|
|
Biotechnology
|
1.41B
|
59.7
Composite
|
$4.33
|
Profitability
68.1
|
|
ANAB
AnaptysBio, Inc.
Biotechnology
|
1.39B
|
55.8
Composite
|
$46.45
|
Health
67.9
|
|
Biotechnology
|
1.37B
|
52.1
Composite
|
$15.43
|
Health
59.1
|
|
INVA
Innoviva, Inc.
Biotechnology
|
1.36B
|
61.4
Composite
|
$19.10
|
Profitability
76.9
|
|
Biotechnology
|
1.36B
|
55.3
Composite
|
$15.33
|
Profitability
67.8
|
|
GHRS
GH Research PLC
Biotechnology
|
1.28B
|
58.8
Composite
|
$18.61
|
Profitability
78.7
|
|
NKTR
Nektar Therapeutics
Biotechnology
|
1.27B
|
58.7
Composite
|
$37.26
|
Profitability
74.9
|
|
Biotechnology
|
1.27B
|
58.9
Composite
|
$13.72
|
Profitability
71.2
|
|
MNKD
MannKind Corporation
Biotechnology
|
1.25B
|
55.5
Composite
|
$3.90
|
Profitability
78.6
|
|
Biotechnology
|
1.24B
|
35.8
Composite
|
$84.52
|
Health
39.9
|
|
SVRA
Savara, Inc.
Biotechnology
|
1.23B
|
52.0
Composite
|
$4.83
|
Profitability
55.1
|
|
OMER
Omeros Corporation
Biotechnology
|
1.22B
|
59.9
Composite
|
$16.92
|
Profitability
80.5
|
|
Biotechnology
|
1.22B
|
52.8
Composite
|
$19.88
|
Profitability
68.1
|
|
URGN
UroGen Pharma Ltd.
Biotechnology
|
1.21B
|
56.3
Composite
|
$24.75
|
Profitability
75.3
|
|
Biotechnology
|
1.19B
|
48.2
Composite
|
$19.73
|
Valuation
60.6
|
|
Biotechnology
|
1.08B
|
62.7
Composite
|
$17.63
|
Profitability
78.3
|
|
VSTM
Verastem, Inc.
Biotechnology
|
1.06B
|
56.9
Composite
|
$8.41
|
Profitability
68.9
|
|
CVAC
CureVac N.V.
Biotechnology
|
1.05B
|
62.7
Composite
|
$4.66
|
Profitability
86.5
|
|
Biotechnology
|
1.00B
|
51.4
Composite
|
$14.00
|
Health
55.7
|
|
Biotechnology
|
987.33M
|
56.4
Composite
|
$25.16
|
Efficiency
62.9
|
|
Biotechnology
|
981.28M
|
49.3
Composite
|
$11.53
|
Health
58.0
|
|
Shell Companies
|
937.42M
|
39.5
Composite
|
$5.33
|
Health
49.1
|
|
Biotechnology
|
914.22M
|
58.9
Composite
|
$8.82
|
Valuation
62.7
|
|
Biotechnology
|
901.76M
|
60.3
Composite
|
$10.57
|
Profitability
73.8
|
|
Biotechnology
|
896.79M
|
55.2
Composite
|
$76.92
|
Health
66.9
|
|
Biotechnology
|
895.70M
|
42.2
Composite
|
$3.80
|
Efficiency
63.9
|
|
Biotechnology
|
886.60M
|
55.7
Composite
|
$10.54
|
Growth
62.7
|
|
Biotechnology
|
884.20M
|
63.5
Composite
|
$17.03
|
Profitability
79.7
|
|
IMTX
Immatics N.V.
Biotechnology
|
869.35M
|
55.2
Composite
|
$6.36
|
Profitability
71.4
|
|
PHAR
Pharming Group N.V.
Biotechnology
|
869.24M
|
58.9
Composite
|
$12.29
|
Profitability
80.2
|
|
Biotechnology
|
864.40M
|
65.4
Composite
|
$9.00
|
Profitability
83.9
|
|
Biotechnology
|
858.87M
|
57.1
Composite
|
$9.54
|
Profitability
68.7
|
|
PRME
Prime Medicine, Inc.
Biotechnology
|
827.26M
|
50.7
Composite
|
$4.65
|
Valuation
61.1
|
|
ANNX
Annexon, Inc.
Biotechnology
|
796.23M
|
56.0
Composite
|
$4.20
|
Profitability
68.7
|
|
Biotechnology
|
792.02M
|
52.8
Composite
|
$1.78
|
Health
65.4
|
|
ALMS
Alumis Inc.
Biotechnology
|
780.49M
|
48.1
Composite
|
$6.03
|
Valuation
64.7
|
|
Biotechnology
|
760.27M
|
55.1
Composite
|
$11.29
|
Profitability
73.3
|
|
Biotechnology
|
740.70M
|
66.1
Composite
|
$39.65
|
Profitability
84.0
|
|
OABI
OmniAb, Inc.
Biotechnology
|
733.68M
|
63.3
Composite
|
$5.03
|
Profitability
81.0
|
|
Biotechnology
|
732.52M
|
58.3
Composite
|
$20.91
|
Profitability
62.5
|
|
Biotechnology
|
727.85M
|
58.3
Composite
|
$11.31
|
Profitability
75.0
|
|
ARDX
Ardelyx, Inc.
Biotechnology
|
723.95M
|
60.3
Composite
|
$2.88
|
Profitability
77.4
|
|
Biotechnology
|
723.13M
|
55.3
Composite
|
$3.66
|
Profitability
78.9
|
|
Biotechnology
|
718.10M
|
51.3
Composite
|
$12.58
|
Efficiency
58.3
|
|
Biotechnology
|
709.48M
|
62.6
Composite
|
$2.37
|
Profitability
73.5
|
|
Biotechnology
|
706.60M
|
54.8
Composite
|
$6.59
|
Profitability
72.8
|
|
Shell Companies
|
705.82M
|
48.2
Composite
|
$11.41
|
Health
56.4
|
|
Biotechnology
|
698.45M
|
65.4
Composite
|
$9.85
|
Profitability
76.2
|
|
Biotechnology
|
691.50M
|
45.8
Composite
|
$6.72
|
Profitability
62.0
|
|
Biotechnology
|
689.66M
|
69.9
Composite
|
$11.59
|
Profitability
85.1
|
|
Biotechnology
|
680.30M
|
55.6
Composite
|
$6.56
|
Profitability
66.0
|
|
Biotechnology
|
676.74M
|
55.5
Composite
|
$12.25
|
Growth
63.9
|
|
Biotechnology
|
672.56M
|
69.7
Composite
|
$13.64
|
Efficiency
100.0
|
|
Biotechnology
|
669.54M
|
52.9
Composite
|
$8.75
|
Valuation
62.4
|
|
Biotechnology
|
668.20M
|
57.4
Composite
|
$8.06
|
Health
66.2
|
|
Biotechnology
|
663.70M
|
47.6
Composite
|
$3.37
|
Profitability
53.4
|
|
Biotechnology
|
662.01M
|
47.1
Composite
|
$10.28
|
Growth
55.2
|
|
Biotechnology
|
657.10M
|
55.1
Composite
|
$10.45
|
Profitability
64.7
|
|
KURA
Kura Oncology, Inc.
Biotechnology
|
646.70M
|
55.4
Composite
|
$7.27
|
Profitability
64.2
|
|
Biotechnology
|
641.36M
|
56.2
Composite
|
$7.33
|
Profitability
64.2
|
|
Biotechnology
|
638.96M
|
53.6
Composite
|
$10.21
|
Valuation
60.5
|
|
GERN
Geron Corporation
Biotechnology
|
636.00M
|
59.9
Composite
|
$0.99
|
Profitability
78.6
|
|
Biotechnology
|
609.93M
|
53.9
Composite
|
$25.96
|
Profitability
63.4
|
|
Shell Companies
|
594.48M
|
53.1
Composite
|
$11.90
|
Growth
71.0
|
|
CLYM
Climb Bio, Inc.
Biotechnology
|
591.02M
|
59.9
Composite
|
$10.29
|
Profitability
79.4
|
|
Biotechnology
|
572.40M
|
58.8
Composite
|
$8.65
|
Profitability
75.6
|
|
Biotechnology
|
561.80M
|
71.7
Composite
|
$40.17
|
Profitability
79.8
|
|
Biotechnology
|
556.60M
|
54.9
Composite
|
$2.85
|
Profitability
63.1
|
|
ENTX
Entera Bio Ltd.
Biotechnology
|
543.70M
|
45.8
Composite
|
$3.14
|
Valuation
69.4
|
|
SRZN
Surrozen, Inc.
Biotechnology
|
542.35M
|
50.7
Composite
|
$31.00
|
Profitability
73.6
|
|
VALN
Valneva SE
Biotechnology
|
530.74M
|
52.4
Composite
|
$5.51
|
Profitability
66.2
|
|
Biotechnology
|
523.25M
|
55.9
Composite
|
$9.00
|
Profitability
74.6
|
|
Biotechnology
|
509.89M
|
48.7
Composite
|
$3.32
|
Valuation
63.5
|
|
Biotechnology
|
509.65M
|
58.8
Composite
|
$4.76
|
Profitability
80.8
|
|
NGNE
Neurogene Inc.
Biotechnology
|
506.49M
|
50.0
Composite
|
$25.31
|
Valuation
63.9
|
|
Biotechnology
|
504.74M
|
55.5
Composite
|
$9.36
|
Profitability
68.4
|
|
RGNX
REGENXBIO Inc.
Biotechnology
|
503.00M
|
57.9
Composite
|
$7.62
|
Profitability
73.6
|
|
MDXG
MiMedx Group, Inc
Biotechnology
|
483.00M
|
59.7
Composite
|
$3.31
|
Profitability
79.0
|
|
Biotechnology
|
479.38M
|
62.3
Composite
|
$71.42
|
Growth
75.1
|
|
Biotechnology
|
477.20M
|
55.0
Composite
|
$2.19
|
Profitability
68.3
|
|
Shell Companies
|
475.72M
|
57.6
Composite
|
$11.46
|
Valuation
71.5
|
|
STTK
Shattuck Labs, Inc.
Biotechnology
|
463.68M
|
56.1
Composite
|
$4.62
|
Health
65.8
|
|
Biotechnology
|
462.37M
|
51.9
Composite
|
$7.49
|
Health
59.9
|
|
Biotechnology
|
425.90M
|
63.3
Composite
|
$8.25
|
Profitability
82.8
|
|
PRTC
PureTech Health plc
Biotechnology
|
423.21M
|
44.0
Composite
|
$17.38
|
Health
56.3
|
|
ARVN
Arvinas, Inc.
Biotechnology
|
419.80M
|
58.5
Composite
|
$6.41
|
Profitability
84.4
|
|
Biotechnology
|
417.01M
|
60.0
Composite
|
$5.25
|
Profitability
76.4
|
|
Biotechnology
|
416.01M
|
60.2
Composite
|
$3.90
|
Profitability
75.9
|
|
Biotechnology
|
415.80M
|
63.0
Composite
|
$20.42
|
Profitability
82.2
|
|
CRMD
CorMedix Inc.
Biotechnology
|
414.66M
|
68.1
Composite
|
$5.32
|
Profitability
84.0
|
|
Biotechnology
|
409.20M
|
53.5
Composite
|
$7.97
|
Health
62.8
|
|
ALT
Altimmune, Inc.
Biotechnology
|
404.60M
|
54.8
Composite
|
$2.08
|
Growth
65.6
|
|
Biotechnology
|
403.50M
|
58.9
Composite
|
$20.64
|
Profitability
75.3
|
|
Shell Companies
|
398.89M
|
51.9
Composite
|
$10.88
|
Profitability
56.3
|
|
Biotechnology
|
394.70M
|
59.8
Composite
|
$2.57
|
Growth
72.2
|
|
ZURA
Zura Bio Limited
Biotechnology
|
393.97M
|
60.0
Composite
|
$4.09
|
Profitability
77.3
|
|
Shell Companies
|
389.92M
|
37.9
Composite
|
$10.85
|
Efficiency
52.5
|
|
Shell Companies
|
389.92M
|
50.8
Composite
|
$10.80
|
Profitability
55.3
|
|
Biotechnology
|
381.38M
|
58.2
Composite
|
$3.10
|
Profitability
72.9
|
|
RZLT
Rezolute, Inc.
Biotechnology
|
375.30M
|
53.4
Composite
|
$3.88
|
Efficiency
60.0
|
|
Biotechnology
|
373.81M
|
63.4
Composite
|
$9.52
|
Profitability
81.7
|
|
Biotechnology
|
371.70M
|
51.2
Composite
|
$6.93
|
Health
65.4
|
|
Biotechnology
|
370.78M
|
63.1
Composite
|
$3.60
|
Profitability
78.9
|
|
Biotechnology
|
365.34M
|
51.8
Composite
|
$14.86
|
Valuation
66.8
|
|
Biotechnology
|
359.31M
|
58.6
Composite
|
$1.04
|
Profitability
70.2
|
|
Biotechnology
|
347.76M
|
47.2
Composite
|
$4.18
|
Profitability
53.1
|
|
Biotechnology
|
345.68M
|
57.2
Composite
|
$4.31
|
Profitability
74.5
|
|
Shell Companies
|
345.25M
|
43.3
Composite
|
$11.00
|
Growth
64.3
|
|
PROK
ProKidney Corp.
Biotechnology
|
344.65M
|
49.9
Composite
|
$1.14
|
Valuation
63.7
|
|
Biotechnology
|
344.00M
|
61.8
Composite
|
$9.81
|
Profitability
84.6
|
|
Biotechnology
|
340.70M
|
58.6
Composite
|
$1.28
|
Profitability
69.6
|
|
ALEC
Alector, Inc.
Biotechnology
|
339.51M
|
50.2
Composite
|
$2.29
|
Profitability
73.5
|
|
Biotechnology
|
337.79M
|
47.1
Composite
|
$5.68
|
Valuation
60.1
|
|
Biotechnology
|
332.80M
|
54.0
Composite
|
$9.54
|
Profitability
56.3
|
|
Shell Companies
|
331.97M
|
55.3
Composite
|
$10.60
|
Profitability
63.2
|
|
Shell Companies
|
330.00M
|
52.4
Composite
|
$10.75
|
Profitability
60.3
|
|
Shell Companies
|
329.97M
|
46.2
Composite
|
$10.76
|
Profitability
60.0
|
|
Biotechnology
|
324.72M
|
58.5
Composite
|
$3.18
|
Profitability
73.2
|
|
AGEN
Agenus Inc.
Biotechnology
|
321.90M
|
52.8
Composite
|
$7.15
|
Profitability
77.2
|
|
Shell Companies
|
321.68M
|
56.1
Composite
|
$10.75
|
Efficiency
77.5
|
|
Shell Companies
|
321.05M
|
51.7
Composite
|
$10.85
|
Profitability
58.8
|
|
Biotechnology
|
320.40M
|
60.9
Composite
|
$11.00
|
Profitability
77.7
|
|
Biotechnology
|
316.70M
|
44.0
Composite
|
$3.14
|
Valuation
53.7
|
|
OCGN
Ocugen, Inc.
Biotechnology
|
313.86M
|
49.2
Composite
|
$0.93
|
Profitability
58.9
|
|
Shell Companies
|
310.79M
|
48.9
Composite
|
$10.81
|
Profitability
54.7
|
|
GRAF
Graf Global Corp.
Shell Companies
|
310.21M
|
45.7
Composite
|
$10.90
|
Profitability
47.5
|
|
Shell Companies
|
308.64M
|
44.6
Composite
|
$11.15
|
Efficiency
52.0
|
|
Biotechnology
|
304.21M
|
58.3
Composite
|
$1.68
|
Profitability
78.4
|
|
Biotechnology
|
301.80M
|
54.2
Composite
|
$4.88
|
Profitability
62.6
|
|
Biotechnology
|
297.06M
|
52.6
Composite
|
$0.17
|
Growth
64.8
|
|
Biotechnology
|
296.12M
|
49.2
Composite
|
$10.60
|
Profitability
67.6
|
|
Biotechnology
|
294.18M
|
46.6
Composite
|
$10.35
|
Profitability
54.0
|
|
Shell Companies
|
287.78M
|
56.1
Composite
|
$34.49
|
Valuation
60.8
|
|
Shell Companies
|
286.67M
|
41.6
Composite
|
$11.02
|
Growth
52.4
|
|
Shell Companies
|
286.48M
|
52.6
Composite
|
$10.95
|
Profitability
63.5
|
|
Biotechnology
|
284.04M
|
49.0
Composite
|
$2.23
|
Health
58.3
|
|
Biotechnology
|
282.30M
|
54.7
Composite
|
$3.70
|
Profitability
63.4
|
|
Shell Companies
|
281.87M
|
43.2
Composite
|
$10.76
|
Growth
56.9
|
|
Biotechnology
|
277.46M
|
55.1
Composite
|
$2.79
|
Valuation
62.6
|
|
Biotechnology
|
275.69M
|
60.4
Composite
|
$3.03
|
Profitability
76.6
|
|
Shell Companies
|
275.40M
|
51.1
Composite
|
$10.80
|
Health
58.5
|
|
QTTB
Q32 Bio Inc.
Biotechnology
|
275.37M
|
63.1
Composite
|
$9.25
|
Profitability
81.3
|
|
Shell Companies
|
274.56M
|
42.7
Composite
|
$10.75
|
Growth
58.4
|
|
Shell Companies
|
273.99M
|
50.2
Composite
|
$9.52
|
Profitability
59.5
|
|
Biotechnology
|
273.11M
|
56.5
Composite
|
$1.50
|
Profitability
69.5
|
|
Shell Companies
|
271.31M
|
40.5
Composite
|
$8.20
|
Profitability
45.0
|
|
Shell Companies
|
270.00M
|
48.2
Composite
|
$10.81
|
Growth
74.7
|
|
Shell Companies
|
269.37M
|
45.6
Composite
|
$10.70
|
Growth
58.4
|
|
Shell Companies
|
265.28M
|
56.7
Composite
|
$11.00
|
Profitability
59.6
|
|
Shell Companies
|
263.04M
|
52.0
Composite
|
$10.70
|
Health
59.8
|
|
Biotechnology
|
261.80M
|
55.3
Composite
|
$2.38
|
Profitability
66.9
|
|
Biotechnology
|
261.29M
|
59.6
Composite
|
$21.03
|
Profitability
83.3
|
|
Shell Companies
|
259.26M
|
58.9
Composite
|
$7.68
|
Growth
82.7
|
|
Biotechnology
|
257.97M
|
58.4
Composite
|
$1.02
|
Profitability
75.9
|
|
Biotechnology
|
254.78M
|
52.3
Composite
|
$4.06
|
Profitability
59.9
|
|
Biotechnology
|
253.04M
|
46.5
Composite
|
$3.61
|
Efficiency
64.7
|
|
Biotechnology
|
249.48M
|
54.1
Composite
|
$2.39
|
Profitability
66.5
|
|
Shell Companies
|
247.02M
|
50.5
Composite
|
$11.05
|
Growth
58.3
|
|
Biotechnology
|
238.46M
|
56.7
Composite
|
$4.17
|
Profitability
74.3
|
|
Biotechnology
|
238.33M
|
59.3
Composite
|
$3.68
|
Profitability
67.2
|
|
Biotechnology
|
237.10M
|
54.2
Composite
|
$2.89
|
Growth
56.4
|
|
Biotechnology
|
231.00M
|
54.9
Composite
|
$3.82
|
Profitability
74.7
|
|
Biotechnology
|
227.82M
|
43.2
Composite
|
$7.53
|
Valuation
48.7
|
|
Biotechnology
|
222.67M
|
47.5
Composite
|
$15.17
|
Valuation
61.8
|
|
CABA
Cabaletta Bio, Inc.
Biotechnology
|
220.41M
|
49.2
Composite
|
$1.30
|
Health
61.0
|
|
Biotechnology
|
219.90M
|
56.6
Composite
|
$1.84
|
Profitability
61.7
|
|
KRRO
Korro Bio, Inc.
Biotechnology
|
217.20M
|
54.9
Composite
|
$14.75
|
Profitability
60.7
|
|
ACIU
AC Immune SA
Biotechnology
|
214.70M
|
51.0
Composite
|
$2.23
|
Profitability
67.1
|
|
Shell Companies
|
212.80M
|
46.7
Composite
|
$10.91
|
Growth
58.2
|
|
Biotechnology
|
211.70M
|
43.5
Composite
|
$2.60
|
Valuation
58.8
|
|
Biotechnology
|
204.70M
|
62.9
Composite
|
$2.54
|
Profitability
83.4
|
|
Biotechnology
|
202.89M
|
60.6
Composite
|
$4.15
|
Profitability
65.9
|
|
ADCT
ADC Therapeutics SA
Biotechnology
|
201.71M
|
50.8
Composite
|
$1.58
|
Profitability
74.5
|
|
Biotechnology
|
199.70M
|
65.6
Composite
|
$61.01
|
Profitability
75.9
|
|
THAR
Tharimmune, Inc.
Biotechnology
|
198.86M
|
56.3
Composite
|
$3.51
|
Health
60.6
|
|
PYXS
Pyxis Oncology, Inc.
Biotechnology
|
198.30M
|
50.3
Composite
|
$1.66
|
Health
65.1
|
|
PALI
Palisade Bio, Inc.
Biotechnology
|
196.93M
|
55.5
Composite
|
$1.13
|
Profitability
65.5
|
|
IFRX
InflaRx N.V.
Biotechnology
|
192.30M
|
50.4
Composite
|
$1.30
|
Efficiency
65.0
|
|
Biotechnology
|
190.51M
|
60.1
Composite
|
$1.35
|
Profitability
78.2
|
|
Shell Companies
|
186.47M
|
48.2
Composite
|
$8.32
|
Health
58.7
|
|
CGEN
Compugen Ltd.
Biotechnology
|
185.70M
|
66.5
Composite
|
$1.96
|
Profitability
79.1
|
|
Biotechnology
|
185.58M
|
49.8
Composite
|
$9.36
|
Efficiency
63.5
|
|
MDWD
MediWound Ltd.
Biotechnology
|
184.00M
|
60.0
Composite
|
$14.25
|
Profitability
74.5
|
|
Biotechnology
|
183.29M
|
61.8
Composite
|
$23.00
|
Profitability
83.4
|
|
ACOG
Alpha Cognition Inc.
Biotechnology
|
180.54M
|
57.9
Composite
|
$8.29
|
Profitability
82.0
|
|
Shell Companies
|
178.74M
|
46.9
Composite
|
$11.06
|
Profitability
56.8
|
|
Biotechnology
|
176.91M
|
50.6
Composite
|
$3.23
|
Valuation
57.9
|
|
Biotechnology
|
176.32M
|
46.1
Composite
|
$4.89
|
Valuation
59.3
|
|
PEPG
PepGen Inc.
Biotechnology
|
171.07M
|
56.0
Composite
|
$2.47
|
Profitability
64.0
|
|
IVVD
Invivyd, Inc.
Biotechnology
|
165.95M
|
60.8
Composite
|
$0.56
|
Profitability
73.5
|
|
Biotechnology
|
161.89M
|
54.0
Composite
|
$1.72
|
Profitability
69.5
|
|
Biotechnology
|
160.60M
|
63.3
Composite
|
$3.86
|
Profitability
80.8
|
|
Biotechnology
|
159.71M
|
56.8
Composite
|
$1.16
|
Profitability
64.7
|
|
Biotechnology
|
159.50M
|
48.6
Composite
|
$9.62
|
Profitability
72.5
|
|
Biotechnology
|
150.94M
|
51.1
Composite
|
$4.00
|
Efficiency
58.3
|
|
MGNX
MacroGenics, Inc.
Biotechnology
|
148.42M
|
56.2
Composite
|
$2.33
|
Profitability
73.5
|
|
Biotechnology
|
148.30M
|
57.0
Composite
|
$3.28
|
Profitability
77.4
|
|
Shell Companies
|
147.50M
|
47.1
Composite
|
$10.74
|
Profitability
57.1
|
|
Biotechnology
|
145.40M
|
57.5
Composite
|
$29.08
|
Profitability
73.3
|
|
Biotechnology
|
142.66M
|
53.7
Composite
|
$8.34
|
Profitability
72.5
|
|
Biotechnology
|
136.65M
|
58.9
Composite
|
$0.76
|
Growth
60.5
|
|
Biotechnology
|
136.06M
|
44.0
Composite
|
$18.73
|
Efficiency
53.2
|
|
Biotechnology
|
134.74M
|
55.8
Composite
|
$2.30
|
Profitability
74.9
|
|
ADAG
Adagene Inc.
Biotechnology
|
134.29M
|
56.9
Composite
|
$2.00
|
Profitability
72.7
|
|
Biotechnology
|
133.79M
|
53.2
Composite
|
$46.55
|
Health
64.4
|
|
IPHA
Innate Pharma S.A.
Biotechnology
|
131.65M
|
39.6
Composite
|
$1.44
|
Profitability
45.0
|
|
Biotechnology
|
130.51M
|
35.8
Composite
|
$3.51
|
Profitability
44.6
|
|
Biotechnology
|
125.63M
|
42.0
Composite
|
$1.22
|
Health
56.0
|
|
PYPD
PolyPid Ltd.
Biotechnology
|
124.71M
|
51.9
Composite
|
$6.14
|
Valuation
67.2
|
|
HUMA
Humacyte, Inc.
Biotechnology
|
124.51M
|
48.1
Composite
|
$0.45
|
Growth
60.8
|
|
NKTX
Nkarta, Inc.
Biotechnology
|
123.91M
|
49.4
Composite
|
$1.73
|
Efficiency
59.9
|
|
Biotechnology
|
123.23M
|
50.2
Composite
|
$3.21
|
Profitability
71.6
|
|
Shell Companies
|
120.64M
|
50.4
Composite
|
$11.95
|
Health
55.9
|
|
Shell Companies
|
120.29M
|
45.9
Composite
|
$10.97
|
Valuation
50.4
|
|
Biotechnology
|
119.00M
|
50.9
Composite
|
$0.77
|
Profitability
64.5
|
|
CDXS
Codexis, Inc.
Biotechnology
|
118.30M
|
57.1
Composite
|
$1.08
|
Profitability
73.9
|
|
ENGN
enGene Holdings Inc.
Biotechnology
|
117.28M
|
57.5
Composite
|
$1.75
|
Profitability
64.4
|
|
Biotechnology
|
116.04M
|
61.8
Composite
|
$2.87
|
Profitability
74.6
|
|
Biotechnology
|
115.55M
|
42.3
Composite
|
$2.42
|
Growth
60.5
|
|
Biotechnology
|
114.90M
|
51.3
Composite
|
$1.87
|
Profitability
69.5
|
|
Biotechnology
|
114.24M
|
62.2
Composite
|
$2.65
|
Profitability
80.3
|
|
Shell Companies
|
113.98M
|
50.5
Composite
|
$10.65
|
Profitability
56.7
|
|
Biotechnology
|
111.05M
|
58.0
Composite
|
$1.87
|
Profitability
75.1
|
|
Biotechnology
|
110.40M
|
56.5
Composite
|
$3.18
|
Profitability
70.0
|
|
Biotechnology
|
109.97M
|
56.6
Composite
|
$3.50
|
Profitability
71.6
|
|
Shell Companies
|
109.67M
|
47.9
Composite
|
$17.11
|
Valuation
65.3
|
|
Biotechnology
|
107.49M
|
50.6
Composite
|
$0.76
|
Valuation
58.5
|
|
Biotechnology
|
106.60M
|
57.7
Composite
|
$1.15
|
Profitability
81.1
|
|
Biotechnology
|
106.24M
|
35.5
Composite
|
$0.44
|
Efficiency
45.6
|
|
IMUX
Immunic, Inc.
Biotechnology
|
105.74M
|
48.5
Composite
|
$7.75
|
Growth
66.2
|
|
Biotechnology
|
103.87M
|
54.8
Composite
|
$1.63
|
Efficiency
79.3
|
|
Biotechnology
|
102.97M
|
44.3
Composite
|
$2.38
|
Valuation
53.8
|
|
FGMC
FG Merger II Corp.
Shell Companies
|
102.96M
|
50.2
Composite
|
$4.44
|
Efficiency
76.9
|
|
Biotechnology
|
99.68M
|
58.4
Composite
|
$1.74
|
Profitability
77.7
|
|
Biotechnology
|
98.89M
|
54.8
Composite
|
$3.55
|
Profitability
64.3
|
|
Shell Companies
|
98.88M
|
44.5
Composite
|
$11.52
|
Valuation
61.9
|
|
Biotechnology
|
98.39M
|
44.2
Composite
|
$7.18
|
Growth
55.8
|
|
Biotechnology
|
96.81M
|
48.2
Composite
|
$1.69
|
Profitability
52.6
|
|
VANI
Vivani Medical, Inc.
Biotechnology
|
96.52M
|
58.9
Composite
|
$1.07
|
Profitability
67.6
|
|
Biotechnology
|
95.70M
|
64.2
Composite
|
$1.51
|
Profitability
80.7
|
|
Biotechnology
|
95.15M
|
53.9
Composite
|
$1.26
|
Profitability
63.3
|
|
Shell Companies
|
94.98M
|
42.5
Composite
|
$10.85
|
Profitability
48.0
|
|
Biotechnology
|
93.52M
|
54.3
Composite
|
$0.50
|
Efficiency
66.7
|
|
Shell Companies
|
92.22M
|
37.5
Composite
|
$12.94
|
Profitability
53.6
|
|
SEER
Seer, Inc.
Biotechnology
|
90.26M
|
52.3
Composite
|
$1.63
|
Profitability
70.3
|
|
CBUS
Cibus, Inc.
Biotechnology
|
90.19M
|
50.5
Composite
|
$1.18
|
Health
62.9
|
|
Shell Companies
|
90.17M
|
55.3
Composite
|
$10.97
|
Profitability
65.3
|
|
Biotechnology
|
89.98M
|
61.1
Composite
|
$0.37
|
Profitability
81.7
|
|
Biotechnology
|
89.30M
|
53.3
Composite
|
$4.10
|
Profitability
75.6
|
|
Biotechnology
|
89.14M
|
42.0
Composite
|
$1.23
|
Health
47.4
|
|
ICCC
ImmuCell Corporation
Biotechnology
|
89.00M
|
66.5
Composite
|
$9.80
|
Profitability
80.6
|
|
Biotechnology
|
88.19M
|
40.0
Composite
|
$0.69
|
Valuation
49.2
|
|
Biotechnology
|
87.97M
|
45.3
Composite
|
$5.59
|
Valuation
59.7
|
|
GNLX
Genelux Corporation
Biotechnology
|
87.83M
|
50.2
Composite
|
$1.96
|
Valuation
69.9
|
|
Shell Companies
|
86.00M
|
54.4
Composite
|
$11.40
|
Valuation
59.6
|
|
Shell Companies
|
84.88M
|
44.4
Composite
|
$11.61
|
Health
55.8
|
|
RLYB
Rallybio Corporation
Biotechnology
|
84.80M
|
55.9
Composite
|
$15.75
|
Efficiency
67.0
|
|
Shell Companies
|
84.74M
|
47.2
Composite
|
$1.69
|
Valuation
55.1
|
|
Shell Companies
|
84.69M
|
42.8
Composite
|
$9.60
|
Profitability
61.9
|
|
Shell Companies
|
82.87M
|
52.1
Composite
|
$11.02
|
Profitability
56.1
|
|
Biotechnology
|
81.30M
|
55.1
Composite
|
$4.74
|
Profitability
72.4
|
|
Biotechnology
|
80.77M
|
49.2
Composite
|
$0.36
|
Efficiency
66.4
|
|
Biotechnology
|
79.00M
|
49.1
Composite
|
$7.87
|
Profitability
68.3
|
|
Shell Companies
|
78.77M
|
44.9
Composite
|
$21.96
|
Efficiency
84.6
|
|
NRXS
Neuraxis, Inc.
Biotechnology
|
78.36M
|
65.3
Composite
|
$6.24
|
Profitability
76.1
|
|
CLLS
Cellectis S.A.
Biotechnology
|
77.80M
|
51.6
Composite
|
$1.07
|
Profitability
68.9
|
|
Shell Companies
|
75.26M
|
31.5
Composite
|
$12.01
|
Profitability
49.5
|
|
OKYO
OKYO Pharma Limited
Biotechnology
|
75.05M
|
52.3
Composite
|
$1.43
|
Profitability
66.8
|
|
Shell Companies
|
73.21M
|
48.5
Composite
|
$10.93
|
Profitability
56.0
|
|
Shell Companies
|
72.64M
|
52.8
Composite
|
$7.61
|
Health
58.7
|
|
EURKU
Eureka Acquisition Corp
Shell Companies
|
72.60M
|
36.8
Composite
|
$13.30
|
Profitability
42.4
|
|
Biotechnology
|
72.19M
|
43.5
Composite
|
$0.07
|
Profitability
54.9
|
|
Biotechnology
|
71.98M
|
62.6
Composite
|
$14.84
|
Profitability
77.2
|
|
MNOV
MediciNova, Inc.
Biotechnology
|
71.86M
|
52.1
Composite
|
$1.46
|
Profitability
73.7
|
|
Biotechnology
|
70.14M
|
54.0
Composite
|
$2.99
|
Growth
63.4
|
|
Shell Companies
|
69.82M
|
31.1
Composite
|
$10.94
|
Health
72.3
|
|
Biotechnology
|
69.60M
|
57.1
Composite
|
$1.36
|
Profitability
77.0
|
|
Biotechnology
|
69.45M
|
49.5
Composite
|
$16.40
|
Health
56.1
|
|
SBXD
SilverBox Corp IV
Shell Companies
|
69.12M
|
49.4
Composite
|
$10.76
|
Growth
59.3
|
|
Biotechnology
|
68.99M
|
55.0
Composite
|
$1.61
|
Efficiency
74.2
|
|
Shell Companies
|
68.23M
|
36.1
Composite
|
$11.30
|
Profitability
42.2
|
|
Shell Companies
|
67.95M
|
38.3
Composite
|
$12.09
|
Valuation
50.3
|
|
NTRB
Nutriband Inc.
Biotechnology
|
67.46M
|
56.3
Composite
|
$5.55
|
Profitability
73.4
|
|
Biotechnology
|
66.70M
|
58.0
Composite
|
$4.79
|
Profitability
83.4
|
|
Biotechnology
|
65.33M
|
57.0
Composite
|
$0.69
|
Valuation
62.7
|
|
Biotechnology
|
64.48M
|
56.4
Composite
|
$1.06
|
Growth
87.0
|
|
Biotechnology
|
63.11M
|
59.8
Composite
|
$0.55
|
Profitability
73.9
|
|
CING
Cingulate Inc.
Biotechnology
|
61.95M
|
58.2
Composite
|
$4.26
|
Profitability
67.5
|
|
Biotechnology
|
61.80M
|
47.8
Composite
|
$0.80
|
Valuation
56.3
|
|
Biotechnology
|
61.70M
|
61.5
Composite
|
$1.85
|
Profitability
75.9
|
|
Shell Companies
|
60.60M
|
46.6
Composite
|
$11.46
|
Profitability
49.5
|
|
Biotechnology
|
59.98M
|
56.3
Composite
|
$1.03
|
Profitability
64.1
|
|
GOSS
Gossamer Bio, Inc.
Biotechnology
|
59.76M
|
44.4
Composite
|
$9.77
|
Profitability
64.0
|
|
Biotechnology
|
59.38M
|
53.2
Composite
|
$3.07
|
Profitability
62.5
|
|
XBIT
XBiotech Inc.
Biotechnology
|
57.60M
|
51.5
Composite
|
$1.89
|
Profitability
73.0
|
|
Biotechnology
|
57.25M
|
50.7
Composite
|
$1.15
|
Profitability
71.2
|
|
Biotechnology
|
56.72M
|
59.6
Composite
|
$8.62
|
Profitability
79.9
|
|
Biotechnology
|
56.21M
|
57.3
Composite
|
$0.52
|
Growth
69.7
|
|
Biotechnology
|
56.00M
|
46.0
Composite
|
$0.44
|
Profitability
64.1
|
|
BOLD
Boundless Bio, Inc.
Biotechnology
|
55.96M
|
50.4
Composite
|
$2.46
|
Profitability
69.3
|
|
Biotechnology
|
55.60M
|
54.4
Composite
|
$0.29
|
Profitability
71.0
|
|
Biotechnology
|
54.80M
|
54.9
Composite
|
$3.19
|
Profitability
63.3
|
|
IBAC
IB Acquisition Corp.
Shell Companies
|
54.14M
|
38.4
Composite
|
$10.81
|
Valuation
51.3
|
|
Biotechnology
|
53.86M
|
49.7
Composite
|
$7.29
|
Health
59.5
|
|
Biotechnology
|
52.94M
|
48.7
Composite
|
$0.61
|
Growth
64.5
|
|
Biotechnology
|
52.82M
|
54.8
Composite
|
$10.35
|
Profitability
74.7
|
|
Biotechnology
|
52.28M
|
64.3
Composite
|
$0.71
|
Growth
86.4
|
|
RNXT
RenovoRx, Inc.
Biotechnology
|
51.00M
|
58.8
Composite
|
$1.13
|
Profitability
71.6
|
|
Shell Companies
|
50.45M
|
31.2
Composite
|
$11.93
|
Valuation
40.6
|
|
Biotechnology
|
50.14M
|
53.7
Composite
|
$0.81
|
Profitability
67.4
|
|
ATHA
Athira Pharma, Inc.
Biotechnology
|
50.13M
|
52.6
Composite
|
$7.66
|
Profitability
64.9
|
|
Biotechnology
|
49.09M
|
57.4
Composite
|
$1.01
|
Profitability
75.0
|
|
Biotechnology
|
48.10M
|
53.0
Composite
|
$0.45
|
Profitability
58.7
|
|
Shell Companies
|
47.62M
|
45.0
Composite
|
$11.06
|
Profitability
47.0
|
|
IBIO
iBio, Inc.
Biotechnology
|
47.50M
|
47.9
Composite
|
$0.74
|
Growth
63.9
|
|
TIL
Instil Bio, Inc.
Biotechnology
|
46.32M
|
51.1
Composite
|
$6.83
|
Efficiency
55.9
|
|
Biotechnology
|
46.21M
|
44.3
Composite
|
$1.00
|
Efficiency
88.7
|
|
Biotechnology
|
45.89M
|
51.0
Composite
|
$0.73
|
Profitability
67.5
|
|
Biotechnology
|
45.19M
|
44.3
Composite
|
$0.28
|
Efficiency
51.6
|
|
Shell Companies
|
45.15M
|
38.8
Composite
|
$11.57
|
Valuation
62.0
|
|
Biotechnology
|
45.00M
|
56.2
Composite
|
$1.43
|
Profitability
79.3
|
|
Biotechnology
|
44.95M
|
51.5
Composite
|
$1.03
|
Valuation
68.2
|
|
Biotechnology
|
44.00M
|
49.1
Composite
|
$2.43
|
Profitability
65.1
|
|
Shell Companies
|
43.64M
|
49.3
Composite
|
$12.20
|
Valuation
68.4
|
|
Biotechnology
|
43.51M
|
49.3
Composite
|
$1.28
|
Profitability
68.5
|
|
Shell Companies
|
43.40M
|
56.3
Composite
|
$11.59
|
Growth
65.1
|
|
Shell Companies
|
42.08M
|
49.1
Composite
|
$11.52
|
Health
55.8
|
|
APLM
Apollomics Inc.
Biotechnology
|
41.72M
|
44.1
Composite
|
$19.00
|
Profitability
63.7
|
|
BMEA
Biomea Fusion, Inc.
Biotechnology
|
41.08M
|
53.8
Composite
|
$0.57
|
Profitability
63.5
|
|
EXOZ
eXoZymes, Inc.
Biotechnology
|
40.84M
|
56.6
Composite
|
$4.40
|
Efficiency
89.8
|
|
Shell Companies
|
39.83M
|
45.2
Composite
|
$11.32
|
Valuation
55.8
|
|
Biotechnology
|
39.69M
|
53.7
Composite
|
$1.51
|
Valuation
64.6
|
|
Biotechnology
|
39.37M
|
58.2
Composite
|
$0.65
|
Growth
74.9
|
|
Shell Companies
|
39.33M
|
28.6
Composite
|
$12.55
|
Profitability
40.0
|
|
Shell Companies
|
39.02M
|
53.9
Composite
|
$10.50
|
Valuation
67.0
|
|
Biotechnology
|
38.90M
|
43.6
Composite
|
$1.85
|
Valuation
64.1
|
|
Shell Companies
|
38.63M
|
43.9
Composite
|
$12.20
|
Valuation
55.8
|
|
Shell Companies
|
38.27M
|
44.2
Composite
|
$11.14
|
Valuation
55.5
|
|
Biotechnology
|
38.23M
|
55.5
Composite
|
$0.63
|
Profitability
79.2
|
|
Shell Companies
|
38.13M
|
31.9
Composite
|
$13.27
|
Profitability
43.9
|
|
Biotechnology
|
37.30M
|
48.9
Composite
|
$4.16
|
Valuation
56.7
|
|
Shell Companies
|
37.05M
|
38.9
Composite
|
$13.45
|
Valuation
61.5
|
|
SNPX
Synaptogenix, Inc.
Biotechnology
|
36.76M
|
0.0
Composite
|
$24.55
|
No pillar score
-
|
|
VERU
Veru Inc.
Biotechnology
|
36.10M
|
58.4
Composite
|
$2.12
|
Profitability
75.1
|
|
ANVS
Annovis Bio, Inc.
Biotechnology
|
36.00M
|
47.6
Composite
|
$0.84
|
Growth
54.5
|
|
Biotechnology
|
35.05M
|
51.4
Composite
|
$1.38
|
Health
58.2
|
|
Biotechnology
|
35.03M
|
52.4
Composite
|
$4.10
|
Growth
70.0
|
|
INMB
INmune Bio Inc.
Biotechnology
|
34.75M
|
49.2
Composite
|
$1.13
|
Valuation
56.0
|
|
Biotechnology
|
34.50M
|
46.2
Composite
|
$3.95
|
Growth
69.2
|
|
Biotechnology
|
33.94M
|
51.1
Composite
|
$1.40
|
Profitability
65.3
|
|
NNVC
NanoViricides, Inc.
Biotechnology
|
33.70M
|
54.1
Composite
|
$1.32
|
Efficiency
71.2
|
|
Shell Companies
|
33.24M
|
42.9
Composite
|
$12.14
|
Valuation
64.9
|
|
ACET
Adicet Bio, Inc.
Biotechnology
|
32.83M
|
59.1
Composite
|
$3.05
|
Profitability
73.1
|
|
Biotechnology
|
32.27M
|
44.8
Composite
|
$29.31
|
Valuation
57.3
|
|
Shell Companies
|
31.82M
|
44.1
Composite
|
$10.40
|
Health
54.1
|
|
Biotechnology
|
31.00M
|
46.6
Composite
|
$0.36
|
Efficiency
58.5
|
|
Shell Companies
|
29.15M
|
30.5
Composite
|
$7.33
|
Valuation
46.4
|
|
EDSA
Edesa Biotech, Inc.
Biotechnology
|
28.91M
|
45.2
Composite
|
$2.14
|
Profitability
55.2
|
|
Shell Companies
|
28.62M
|
35.6
Composite
|
$12.50
|
Valuation
56.9
|
|
FGEN
FibroGen, Inc
Biotechnology
|
27.90M
|
54.8
Composite
|
$7.21
|
Profitability
66.8
|
|
Biotechnology
|
27.53M
|
50.3
Composite
|
$3.86
|
Profitability
61.4
|
|
Shell Companies
|
27.52M
|
42.8
Composite
|
$9.19
|
Valuation
60.6
|
|
PLRZ
Polyrizon Ltd.
Biotechnology
|
26.82M
|
53.7
Composite
|
$11.04
|
Profitability
64.5
|
|
MGX
Metagenomi, Inc.
Biotechnology
|
26.80M
|
56.1
Composite
|
$0.71
|
Profitability
75.1
|
|
Biotechnology
|
26.06M
|
47.3
Composite
|
$0.74
|
Profitability
61.2
|
|
ABVC
ABVC Biopharma, Inc.
Biotechnology
|
25.90M
|
54.0
Composite
|
$0.97
|
Profitability
80.3
|
|
Biotechnology
|
25.90M
|
45.1
Composite
|
$0.05
|
Efficiency
50.7
|
|
BYSI
BeyondSpring, Inc.
Biotechnology
|
25.74M
|
43.8
Composite
|
$0.63
|
Profitability
53.4
|
|
MEIP
MEI Pharma, Inc.
Biotechnology
|
25.70M
|
0.0
Composite
|
$3.07
|
No pillar score
-
|
|
Biotechnology
|
25.61M
|
56.8
Composite
|
$1.17
|
Profitability
76.3
|
|
Biotechnology
|
25.50M
|
48.9
Composite
|
$1.45
|
Health
67.6
|
|
Biotechnology
|
25.42M
|
55.0
Composite
|
$4.07
|
Profitability
74.2
|
|
Biotechnology
|
25.23M
|
45.6
Composite
|
$1.49
|
Profitability
64.0
|
|
Shell Companies
|
25.07M
|
38.8
Composite
|
$11.55
|
Valuation
52.6
|
|
EVAX
Evaxion Biotech A/S
Biotechnology
|
25.02M
|
54.7
Composite
|
$3.00
|
Profitability
71.5
|
|
CELU
Celularity Inc.
Biotechnology
|
24.67M
|
50.0
Composite
|
$0.76
|
Profitability
73.2
|
|
IMMP
Immutep Limited
Biotechnology
|
24.60M
|
47.6
Composite
|
$3.34
|
Profitability
57.8
|
|
Shell Companies
|
24.56M
|
34.2
Composite
|
$0.45
|
Health
64.7
|
|
NXTC
NextCure, Inc.
Biotechnology
|
24.40M
|
51.8
Composite
|
$5.33
|
Profitability
63.7
|
|
Shell Companies
|
23.90M
|
50.9
Composite
|
$10.26
|
Health
75.2
|
|
Shell Companies
|
23.38M
|
56.8
Composite
|
$5.63
|
Profitability
67.5
|
|
Biotechnology
|
22.41M
|
45.3
Composite
|
$27.86
|
Health
53.9
|
|
CRVO
CervoMed Inc.
Biotechnology
|
21.47M
|
50.4
Composite
|
$1.42
|
Profitability
63.0
|
|
Biotechnology
|
21.20M
|
44.2
Composite
|
$2.12
|
Efficiency
54.2
|
|
IGC
IGC Pharma, Inc.
Biotechnology
|
20.70M
|
49.9
Composite
|
$0.20
|
Profitability
64.6
|
|
Biotechnology
|
20.03M
|
43.5
Composite
|
$1.04
|
Valuation
56.7
|
|
Biotechnology
|
19.70M
|
56.5
Composite
|
$1.98
|
Health
65.3
|
|
Biotechnology
|
19.34M
|
50.1
Composite
|
$0.58
|
Growth
64.6
|
|
Biotechnology
|
18.70M
|
54.8
Composite
|
$16.86
|
Health
63.7
|
|
Biotechnology
|
18.14M
|
47.2
Composite
|
$0.82
|
Health
55.1
|
|
Biotechnology
|
18.08M
|
48.4
Composite
|
$0.33
|
Valuation
65.6
|
|
BIVI
BioVie Inc.
Biotechnology
|
17.91M
|
37.1
Composite
|
$1.33
|
Growth
48.0
|
|
Biotechnology
|
17.78M
|
50.0
Composite
|
$0.19
|
Valuation
62.7
|
|
Biotechnology
|
17.54M
|
46.4
Composite
|
$3.65
|
Health
59.0
|
|
Biotechnology
|
16.91M
|
42.0
Composite
|
$6.54
|
Health
61.0
|
|
Biotechnology
|
16.84M
|
43.4
Composite
|
$7.37
|
Growth
56.6
|
|
Biotechnology
|
16.67M
|
50.8
Composite
|
$23.94
|
Profitability
65.4
|
|
Biotechnology
|
16.32M
|
46.1
Composite
|
$0.38
|
Profitability
70.1
|
|
Biotechnology
|
16.17M
|
52.8
Composite
|
$0.22
|
Profitability
62.0
|
|
ATYR
aTyr Pharma, Inc.
Biotechnology
|
15.60M
|
50.5
Composite
|
$6.35
|
Efficiency
71.1
|
|
Biotechnology
|
15.35M
|
48.7
Composite
|
$0.96
|
Health
60.1
|
|
PLUR
Pluri Inc.
Biotechnology
|
15.25M
|
41.0
Composite
|
$1.24
|
Valuation
59.5
|
|
Biotechnology
|
15.04M
|
50.1
Composite
|
$2.78
|
Profitability
60.6
|
|
Biotechnology
|
14.96M
|
50.9
Composite
|
$0.55
|
Profitability
62.5
|
|
Biotechnology
|
14.90M
|
50.7
Composite
|
$0.89
|
Profitability
61.0
|
|
HOOK
HOOKIPA Pharma Inc.
Biotechnology
|
13.86M
|
58.4
Composite
|
$1.15
|
Profitability
73.3
|
|
SYBX
Synlogic, Inc.
Biotechnology
|
13.47M
|
49.4
Composite
|
$1.10
|
Efficiency
58.2
|
|
Biotechnology
|
13.26M
|
45.4
Composite
|
$4.15
|
Growth
48.9
|
|
BCDA
BioCardia, Inc.
Biotechnology
|
12.90M
|
44.0
Composite
|
$0.85
|
Profitability
55.6
|
|
LPCN
Lipocine Inc.
Biotechnology
|
12.90M
|
53.2
Composite
|
$1.57
|
Profitability
62.2
|
|
Biotechnology
|
12.83M
|
46.6
Composite
|
$0.90
|
Profitability
60.0
|
|
PASG
Passage Bio, Inc.
Biotechnology
|
12.79M
|
49.8
Composite
|
$3.98
|
Profitability
63.0
|
|
Biotechnology
|
12.74M
|
47.5
Composite
|
$0.19
|
Efficiency
74.7
|
|
Biotechnology
|
12.38M
|
44.9
Composite
|
$0.34
|
Valuation
56.6
|
|
GUTS
Fractyl Health, Inc.
Biotechnology
|
12.33M
|
45.6
Composite
|
$0.93
|
Valuation
66.3
|
|
Biotechnology
|
12.01M
|
46.4
Composite
|
$0.12
|
Health
51.8
|
|
Biotechnology
|
11.80M
|
48.3
Composite
|
$1.25
|
Growth
65.8
|
|
RENB
Renovaro Inc.
Biotechnology
|
11.60M
|
0.0
Composite
|
$0.32
|
No pillar score
-
|
|
Biotechnology
|
11.29M
|
47.7
Composite
|
$2.96
|
Valuation
62.4
|
|
Biotechnology
|
11.22M
|
54.2
Composite
|
$0.28
|
Profitability
73.2
|
|
PPBT
Purple Biotech Ltd.
Biotechnology
|
10.99M
|
53.7
Composite
|
$1.31
|
Profitability
71.0
|
|
Biotechnology
|
10.25M
|
52.5
Composite
|
$0.86
|
Profitability
61.6
|
|
Biotechnology
|
10.20M
|
45.2
Composite
|
$6.27
|
Profitability
54.5
|
|
Biotechnology
|
9.89M
|
55.4
Composite
|
$1.88
|
Profitability
62.9
|
|
Biotechnology
|
9.80M
|
50.4
Composite
|
$0.64
|
Profitability
60.0
|
|
Biotechnology
|
9.79M
|
54.8
Composite
|
$3.00
|
Growth
67.6
|
|
Biotechnology
|
9.56M
|
47.3
Composite
|
$1.32
|
Profitability
65.8
|
|
MTVA
MetaVia Inc.
Biotechnology
|
9.42M
|
55.2
Composite
|
$1.43
|
Health
63.0
|
|
BLRX
BioLineRx Ltd.
Biotechnology
|
9.35M
|
55.4
Composite
|
$1.71
|
Profitability
61.5
|
|
Biotechnology
|
9.30M
|
42.0
Composite
|
$1.03
|
Valuation
46.1
|
|
Biotechnology
|
9.30M
|
47.1
Composite
|
$0.80
|
Health
57.9
|
|
CALC
CalciMedica, Inc.
Biotechnology
|
9.29M
|
49.3
Composite
|
$1.36
|
Valuation
65.2
|
|
Biotechnology
|
9.16M
|
46.9
Composite
|
$1.44
|
Profitability
62.8
|
|
INAB
IN8bio, Inc.
Biotechnology
|
9.13M
|
55.6
Composite
|
$0.93
|
Profitability
61.9
|
|
AEON
AEON Biopharma, Inc.
Biotechnology
|
8.77M
|
51.7
Composite
|
$0.18
|
Profitability
62.8
|
|
Biotechnology
|
8.50M
|
40.9
Composite
|
$8.70
|
Growth
62.4
|
|
GTBP
GT Biopharma, Inc.
Biotechnology
|
8.00M
|
53.3
Composite
|
$4.42
|
Profitability
67.4
|
|
Biotechnology
|
7.64M
|
49.8
Composite
|
$0.17
|
Growth
65.4
|
|
Biotechnology
|
7.51M
|
48.0
Composite
|
$3.97
|
Efficiency
57.3
|
|
Biotechnology
|
7.40M
|
46.9
Composite
|
$4.50
|
Health
60.5
|
|
SNGX
Soligenix, Inc.
Biotechnology
|
7.30M
|
48.2
Composite
|
$0.34
|
Profitability
62.8
|
|
Biotechnology
|
7.30M
|
45.4
Composite
|
$0.16
|
Growth
51.4
|
|
LTRN
Lantern Pharma Inc.
Biotechnology
|
7.26M
|
48.6
Composite
|
$0.57
|
Profitability
70.0
|
|
FBLG
FibroBiologics, Inc.
Biotechnology
|
6.81M
|
49.6
Composite
|
$0.98
|
Valuation
63.1
|
|
ALZN
Alzamend Neuro, Inc.
Biotechnology
|
6.80M
|
48.2
Composite
|
$1.41
|
Efficiency
92.6
|
|
IMRN
Immuron Limited
Biotechnology
|
6.70M
|
52.9
Composite
|
$0.83
|
Profitability
72.9
|
|
Biotechnology
|
6.52M
|
55.7
Composite
|
$0.52
|
Profitability
65.2
|
|
Biotechnology
|
6.40M
|
47.6
Composite
|
$0.33
|
Profitability
61.2
|
|
Biotechnology
|
6.39M
|
51.5
Composite
|
$8.41
|
Growth
57.3
|
|
Biotechnology
|
6.37M
|
52.2
Composite
|
$1.42
|
Profitability
70.8
|
|
Biotechnology
|
6.30M
|
43.6
Composite
|
$0.38
|
Valuation
53.2
|
|
XCUR
Exicure, Inc.
Biotechnology
|
6.22M
|
47.0
Composite
|
$0.95
|
Profitability
58.9
|
|
Biotechnology
|
6.11M
|
41.0
Composite
|
$2.90
|
Efficiency
52.9
|
|
Biotechnology
|
5.94M
|
51.5
Composite
|
$0.83
|
Profitability
70.9
|
|
Shell Companies
|
5.87M
|
43.9
Composite
|
$0.07
|
Growth
56.9
|
|
Biotechnology
|
5.80M
|
43.6
Composite
|
$1.55
|
Valuation
59.2
|
|
LGVN
Longeveron Inc.
Biotechnology
|
5.77M
|
48.1
Composite
|
$1.81
|
Efficiency
55.0
|
|
Biotechnology
|
5.73M
|
48.3
Composite
|
$3.92
|
Growth
64.3
|
|
Biotechnology
|
5.59M
|
62.0
Composite
|
$1.06
|
Growth
78.1
|
|
Biotechnology
|
5.40M
|
45.4
Composite
|
$1.93
|
Profitability
57.2
|
|
Biotechnology
|
5.12M
|
42.0
Composite
|
$1.62
|
Health
57.8
|
|
PULM
Pulmatrix, Inc.
Biotechnology
|
5.04M
|
49.2
Composite
|
$1.38
|
Profitability
59.9
|
|
Biotechnology
|
4.98M
|
44.6
Composite
|
$0.16
|
Efficiency
58.1
|
|
Biotechnology
|
4.89M
|
50.5
Composite
|
$1.65
|
Efficiency
71.6
|
|
Biotechnology
|
4.82M
|
60.2
Composite
|
$0.37
|
Profitability
71.9
|
|
EVGN
Evogene Ltd.
Biotechnology
|
4.75M
|
50.9
Composite
|
$0.27
|
Profitability
74.2
|
|
IMNN
Imunon, Inc.
Biotechnology
|
4.74M
|
47.3
Composite
|
$0.84
|
Valuation
53.8
|
|
Biotechnology
|
4.72M
|
47.2
Composite
|
$0.16
|
Efficiency
66.2
|
|
AZTR
Azitra Inc
Biotechnology
|
4.44M
|
46.7
Composite
|
$0.73
|
Efficiency
67.0
|
|
Biotechnology
|
4.42M
|
48.1
Composite
|
$1.74
|
Valuation
62.0
|
|
Biotechnology
|
4.40M
|
52.8
Composite
|
$0.99
|
Profitability
67.7
|
|
Biotechnology
|
4.38M
|
57.9
Composite
|
$1.87
|
Profitability
78.9
|
|
Biotechnology
|
4.35M
|
43.9
Composite
|
$0.13
|
Profitability
61.0
|
|
Biotechnology
|
4.17M
|
46.6
Composite
|
$0.08
|
Profitability
53.5
|
|
GRI
GRI Bio, Inc.
Biotechnology
|
4.11M
|
49.8
Composite
|
$1.88
|
Profitability
59.5
|
|
Biotechnology
|
4.10M
|
48.2
Composite
|
$0.62
|
Health
66.4
|
|
NCNA
NuCana plc
Biotechnology
|
3.90M
|
55.1
Composite
|
$0.94
|
Growth
73.7
|
|
Biotechnology
|
3.86M
|
48.1
Composite
|
$0.36
|
Profitability
70.7
|
|
Biotechnology
|
3.75M
|
53.8
Composite
|
$3.46
|
Profitability
67.5
|
|
CRIS
Curis, Inc.
Biotechnology
|
3.72M
|
46.4
Composite
|
$0.91
|
Health
58.8
|
|
Biotechnology
|
3.72M
|
56.7
Composite
|
$8.28
|
Efficiency
94.1
|
|
Biotechnology
|
3.50M
|
44.8
Composite
|
$0.98
|
Health
59.9
|
|
TRAW
Traws Pharma, Inc.
Biotechnology
|
3.40M
|
43.6
Composite
|
$0.22
|
Valuation
61.6
|
|
BCAB
BioAtla, Inc.
Biotechnology
|
3.33M
|
52.5
Composite
|
$2.00
|
Profitability
70.2
|
|
Biotechnology
|
3.30M
|
49.9
Composite
|
$1.24
|
Profitability
64.9
|
|
Biotechnology
|
3.11M
|
43.8
Composite
|
$1.68
|
Valuation
54.5
|
|
Biotechnology
|
3.07M
|
52.6
Composite
|
$0.76
|
Profitability
68.2
|
|
Biotechnology
|
3.07M
|
52.4
Composite
|
$1.88
|
Efficiency
60.1
|
|
KALA
KALA BIO, Inc.
Biotechnology
|
3.02M
|
48.7
Composite
|
$0.16
|
Profitability
56.9
|
|
MBIO
Mustang Bio, Inc.
Biotechnology
|
3.00M
|
61.1
Composite
|
$0.40
|
Profitability
80.5
|
|
Biotechnology
|
2.90M
|
42.2
Composite
|
$2.20
|
Valuation
55.7
|
|
PHGE
BiomX Inc.
Biotechnology
|
2.84M
|
40.8
Composite
|
$0.31
|
Valuation
47.9
|
|
ONCO
Onconetix, Inc.
Biotechnology
|
2.74M
|
44.3
Composite
|
$6.95
|
Health
58.7
|
|
VCNX
Vaccinex, Inc.
Biotechnology
|
2.68M
|
43.4
Composite
|
$1.00
|
Valuation
100.0
|
|
Biotechnology
|
2.59M
|
47.6
Composite
|
$0.70
|
Efficiency
66.5
|
|
Biotechnology
|
2.35M
|
49.6
Composite
|
$5.58
|
Profitability
70.3
|
|
HCWB
HCW Biologics Inc.
Biotechnology
|
2.28M
|
44.5
Composite
|
$1.02
|
Health
56.1
|
|
Biotechnology
|
2.21M
|
60.5
Composite
|
$3.89
|
Growth
73.0
|
|
Biotechnology
|
2.15M
|
44.3
Composite
|
$0.25
|
Profitability
51.4
|
|
Biotechnology
|
2.09M
|
55.4
Composite
|
$0.59
|
Growth
63.5
|
|
Biotechnology
|
1.90M
|
46.9
Composite
|
$1.52
|
Health
62.9
|
|
Shell Companies
|
1.77M
|
58.4
Composite
|
$1.67
|
Profitability
62.9
|
|
MLEC
Moolec Science SA
Biotechnology
|
1.77M
|
46.7
Composite
|
$0.85
|
Profitability
68.4
|
|
GNPX
Genprex, Inc.
Biotechnology
|
1.70M
|
47.8
Composite
|
$2.07
|
Health
59.2
|
|
Biotechnology
|
1.65M
|
52.3
Composite
|
$0.91
|
Profitability
65.0
|
|
KAPA
Kairos Pharma, Ltd.
Biotechnology
|
1.65M
|
59.0
Composite
|
$0.49
|
Efficiency
97.2
|
|
Biotechnology
|
1.58M
|
53.4
Composite
|
$1.27
|
Profitability
68.4
|
|
OGEN
Oragenics Inc.
Biotechnology
|
1.58M
|
55.7
Composite
|
$0.35
|
Growth
75.0
|
|
NKGN
NKGen Biotech, Inc.
Biotechnology
|
1.44M
|
38.4
Composite
|
$0.01
|
Valuation
51.0
|
|
GOVX
GeoVax Labs, Inc.
Biotechnology
|
1.44M
|
44.5
Composite
|
$0.16
|
Growth
49.8
|
|
Biotechnology
|
1.41M
|
50.6
Composite
|
$0.43
|
Profitability
64.9
|
|
ELAB
PMGC Holdings Inc.
Biotechnology
|
1.30M
|
55.9
Composite
|
$1.61
|
Profitability
67.4
|
|
Biotechnology
|
1.20M
|
44.2
Composite
|
$0.06
|
Profitability
65.3
|
|
Biotechnology
|
1.20M
|
44.4
Composite
|
$1.19
|
Efficiency
73.3
|
|
Biotechnology
|
1.00M
|
46.3
Composite
|
$1.91
|
Profitability
49.5
|
|
Biotechnology
|
977,512
|
50.6
Composite
|
$0.54
|
Growth
61.5
|
|
Biotechnology
|
807,349
|
42.3
Composite
|
$0.14
|
Valuation
64.9
|
|
ADTX
Aditxt, Inc.
Biotechnology
|
698,584
|
33.4
Composite
|
$0.00
|
Valuation
46.9
|
|
Biotechnology
|
631,135
|
45.1
Composite
|
$0.79
|
Efficiency
55.9
|
|
IOBT
IO Biotech, Inc.
Biotechnology
|
467,667
|
48.1
Composite
|
$0.01
|
Health
66.2
|
|
Biotechnology
|
337,228
|
43.1
Composite
|
$0.19
|
Efficiency
59.9
|
|
Biotechnology
|
318,946
|
45.7
Composite
|
$2.48
|
Health
58.5
|
|
Biotechnology
|
258,131
|
49.9
Composite
|
$0.00
|
Efficiency
92.7
|
|
Biotechnology
|
251,380
|
56.6
Composite
|
$0.44
|
Health
68.4
|
|
SPRC
SciSparc Ltd.
Biotechnology
|
243,195
|
38.2
Composite
|
$0.42
|
Health
46.4
|
|
JAGX
Jaguar Health, Inc.
Biotechnology
|
210,293
|
47.6
Composite
|
$0.40
|
Profitability
54.9
|
|
Shell Companies
|
140,010
|
38.2
Composite
|
$9.72
|
Profitability
56.0
|
|
Biotechnology
|
92,946
|
36.9
Composite
|
$0.00
|
Health
42.8
|
|
VINC
Vincerx Pharma, Inc.
Biotechnology
|
78,514
|
45.3
Composite
|
$0.01
|
Efficiency
75.3
|
|
Biotechnology
|
73,655
|
47.4
Composite
|
$1.31
|
Profitability
69.8
|
|
Biotechnology
|
26,993
|
37.5
Composite
|
$0.00
|
Valuation
49.9
|
|
Biotechnology
|
16,170
|
43.1
Composite
|
$0.00
|
Valuation
62.5
|
|
Biotechnology
|
10,733
|
49.1
Composite
|
$0.00
|
Valuation
100.0
|
|
Biotechnology
|
8,369
|
47.4
Composite
|
$0.00
|
Profitability
66.8
|
|
Biotechnology
|
8,096
|
38.2
Composite
|
$0.00
|
Valuation
55.0
|
|
Biotechnology
|
2,485
|
36.1
Composite
|
$0.00
|
Valuation
100.0
|
|
Biotechnology
|
2,310
|
52.3
Composite
|
$0.00
|
Valuation
60.6
|
|
Shell Companies
|
2,183
|
37.0
Composite
|
$0.00
|
Efficiency
65.2
|
|
Biotechnology
|
941
|
39.0
Composite
|
$0.00
|
Health
55.4
|
|
TRVN
Trevena, Inc.
Biotechnology
|
479
|
41.6
Composite
|
$0.01
|
Profitability
55.0
|
|
ATNFW
180 Life Sciences Corp.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
TSVT
2seventy bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
CSLMF
6816
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
ETNB
89bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
45.8
Composite
|
$10.67
|
Health
75.2
|
|
Shell Companies
|
-
|
47.8
Composite
|
$10.66
|
Health
62.2
|
|
Biotechnology
|
-
|
62.8
Composite
|
-
|
Profitability
78.3
|
|
ABPWW
Abpro Holdings, Inc.
Biotechnology
|
-
|
42.6
Composite
|
$0.01
|
Profitability
46.1
|
|
SLRN
ACELYRIN, INC.
Biotechnology
|
-
|
37.2
Composite
|
-
|
Health
54.5
|
|
Biotechnology
|
-
|
59.8
Composite
|
-
|
Health
65.2
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
53.6
Composite
|
-
|
Profitability
69.1
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
AFMD
Affimed N.V.
Biotechnology
|
-
|
41.9
Composite
|
$0.18
|
Health
63.6
|
|
Shell Companies
|
-
|
50.9
Composite
|
$0.14
|
Health
58.7
|
|
Shell Companies
|
-
|
47.6
Composite
|
$11.69
|
Health
53.7
|
|
Shell Companies
|
-
|
47.8
Composite
|
-
|
Growth
100.0
|
|
Shell Companies
|
-
|
47.8
Composite
|
-
|
Growth
100.0
|
|
Shell Companies
|
-
|
34.7
Composite
|
$12.89
|
Profitability
43.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
$19.26
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$18.15
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.04
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
28.1
Composite
|
$13.50
|
Health
45.4
|
|
ALDFU
Aldel Financial II Inc.
Shell Companies
|
-
|
56.2
Composite
|
$10.90
|
Growth
77.7
|
|
Shell Companies
|
-
|
57.0
Composite
|
$0.12
|
Growth
77.7
|
|
ALLK
Allakos Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
ALVR
AlloVir, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
56.9
Composite
|
$3.28
|
Valuation
81.4
|
|
Shell Companies
|
-
|
46.8
Composite
|
-
|
Efficiency
62.6
|
|
Shell Companies
|
-
|
46.5
Composite
|
-
|
Efficiency
62.6
|
|
Shell Companies
|
-
|
45.2
Composite
|
-
|
Efficiency
62.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
29.9
Composite
|
-
|
Profitability
47.2
|
|
Shell Companies
|
-
|
31.2
Composite
|
$4.50
|
Profitability
47.2
|
|
Shell Companies
|
-
|
42.3
Composite
|
$10.71
|
Growth
58.5
|
|
Biotechnology
|
-
|
48.3
Composite
|
$0.10
|
Growth
54.7
|
|
Biotechnology
|
-
|
39.7
Composite
|
$1.71
|
Health
45.9
|
|
APXIU
APx Acquisition Corp. I
Shell Companies
|
-
|
29.5
Composite
|
-
|
Efficiency
48.6
|
|
Shell Companies
|
-
|
27.4
Composite
|
-
|
Efficiency
48.6
|
|
Shell Companies
|
-
|
24.4
Composite
|
$12.79
|
Health
30.2
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
23.0
Composite
|
-
|
Profitability
30.2
|
|
Shell Companies
|
-
|
26.4
Composite
|
-
|
Profitability
42.1
|
|
Shell Companies
|
-
|
26.4
Composite
|
-
|
Profitability
42.1
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
55.6
Composite
|
-
|
Valuation
100.0
|
|
Shell Companies
|
-
|
40.4
Composite
|
-
|
Health
48.4
|
|
Shell Companies
|
-
|
40.3
Composite
|
-
|
Health
48.4
|
|
BAYAU
Bayview Acquisition Corp
Shell Companies
|
-
|
33.7
Composite
|
$12.00
|
Health
54.1
|
|
BGNE
BeiGene, Ltd.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
34.0
Composite
|
-
|
Growth
54.2
|
|
Biotechnology
|
-
|
43.2
Composite
|
$0.01
|
Valuation
100.0
|
|
Shell Companies
|
-
|
56.9
Composite
|
$5.88
|
Profitability
64.2
|
|
Shell Companies
|
-
|
58.8
Composite
|
$11.00
|
Growth
100.0
|
|
BLEUU
bleuacacia ltd
Shell Companies
|
-
|
28.5
Composite
|
-
|
Efficiency
44.8
|
|
BLEU
bleuacacia ltd
Shell Companies
|
-
|
28.5
Composite
|
-
|
Efficiency
44.8
|
|
BLEUW
bleuacacia ltd Warrants
Shell Companies
|
-
|
45.4
Composite
|
-
|
Profitability
61.4
|
|
BLUE
bluebird bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
54.0
Composite
|
$10.75
|
Profitability
60.0
|
|
Shell Companies
|
-
|
38.5
Composite
|
$0.00
|
Valuation
100.0
|
|
BOWNU
Bowen Acquisition Corp
Shell Companies
|
-
|
33.4
Composite
|
-
|
Efficiency
50.6
|
|
Biotechnology
|
-
|
56.8
Composite
|
$0.00
|
Valuation
100.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.70
|
No pillar score
-
|
|
Shell Companies
|
-
|
38.2
Composite
|
$12.00
|
Health
55.8
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
42.3
Composite
|
-
|
Health
57.9
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
39.0
Composite
|
$14.39
|
Profitability
53.5
|
|
Shell Companies
|
-
|
38.9
Composite
|
$0.14
|
Profitability
53.5
|
|
Shell Companies
|
-
|
45.5
Composite
|
-
|
Growth
73.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
48.7
Composite
|
$0.01
|
Valuation
100.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.75
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.69
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$180.56
|
No pillar score
-
|
|
Shell Companies
|
-
|
41.9
Composite
|
$11.30
|
Profitability
45.7
|
|
CELUW
Celularity Inc.
Biotechnology
|
-
|
50.8
Composite
|
$0.01
|
Profitability
75.5
|
|
Shell Companies
|
-
|
35.6
Composite
|
$11.05
|
Efficiency
52.5
|
|
Biotechnology
|
-
|
46.6
Composite
|
$0.00
|
Valuation
100.0
|
|
Shell Companies
|
-
|
38.2
Composite
|
$11.28
|
Health
54.7
|
|
CFFSU
CF Acquisition Corp. VII
Shell Companies
|
-
|
38.2
Composite
|
$11.18
|
Health
54.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
41.2
Composite
|
$11.05
|
Growth
58.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
CMRX
Chimerix, Inc.
Biotechnology
|
-
|
46.9
Composite
|
-
|
Health
62.5
|
|
Shell Companies
|
-
|
49.3
Composite
|
$10.81
|
Growth
58.1
|
|
Biotechnology
|
-
|
48.6
Composite
|
$221.38
|
Valuation
51.9
|
|
CINGW
Cingulate Inc. Warrants
Biotechnology
|
-
|
59.5
Composite
|
$0.00
|
Valuation
100.0
|
|
CLRC
ClimateRock
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
CLRCU
ClimateRock
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
CLRCW
ClimateRock Warrant
Shell Companies
|
-
|
0.0
Composite
|
$0.03
|
No pillar score
-
|
|
Shell Companies
|
-
|
46.5
Composite
|
$10.87
|
Growth
57.7
|
|
Shell Companies
|
-
|
49.2
Composite
|
$0.12
|
Growth
57.7
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
48.8
Composite
|
$0.01
|
Profitability
67.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
$2.72
|
No pillar score
-
|
|
CYBN
Cybin Inc.
Biotechnology
|
-
|
57.6
Composite
|
$7.61
|
Valuation
100.0
|
|
Biotechnology
|
-
|
57.5
Composite
|
-
|
Profitability
81.0
|
|
Biotechnology
|
-
|
46.2
Composite
|
-
|
Profitability
60.5
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.43
|
No pillar score
-
|
|
Shell Companies
|
-
|
33.4
Composite
|
$11.84
|
Efficiency
44.9
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.04
|
No pillar score
-
|
|
Biotechnology
|
-
|
54.8
Composite
|
$0.00
|
Profitability
68.9
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
27.4
Composite
|
-
|
Health
38.5
|
|
Shell Companies
|
-
|
27.4
Composite
|
-
|
Health
38.5
|
|
Shell Companies
|
-
|
27.4
Composite
|
-
|
Health
38.5
|
|
Shell Companies
|
-
|
17.6
Composite
|
-
|
Efficiency
32.9
|
|
Shell Companies
|
-
|
17.4
Composite
|
-
|
Efficiency
32.9
|
|
Shell Companies
|
-
|
39.5
Composite
|
-
|
Health
51.7
|
|
DUETU
DUET Acquisition Corp.
Shell Companies
|
-
|
39.5
Composite
|
-
|
Health
51.7
|
|
Shell Companies
|
-
|
39.5
Composite
|
-
|
Health
51.7
|
|
DYNXU
Dynamix Corporation
Shell Companies
|
-
|
0.0
Composite
|
$10.89
|
No pillar score
-
|
|
DYNX
Dynamix Corporation
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.78
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$12.80
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.00
|
No pillar score
-
|
|
Shell Companies
|
-
|
43.3
Composite
|
-
|
Health
55.6
|
|
Biotechnology
|
-
|
59.9
Composite
|
$0.20
|
Valuation
100.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
EPIX
ESSA Pharma Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
40.5
Composite
|
$0.08
|
Valuation
100.0
|
|
EYEN
Eyenovia, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
44.4
Composite
|
$10.77
|
Growth
55.8
|
|
FGMCU
FG Merger II Corp.
Shell Companies
|
-
|
46.6
Composite
|
$8.97
|
Efficiency
76.6
|
|
Shell Companies
|
-
|
36.3
Composite
|
$0.05
|
Valuation
100.0
|
|
Shell Companies
|
-
|
31.4
Composite
|
-
|
Health
56.4
|
|
Shell Companies
|
-
|
31.4
Composite
|
-
|
Health
56.4
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.05
|
No pillar score
-
|
|
Shell Companies
|
-
|
29.6
Composite
|
$11.01
|
Health
41.3
|
|
FICVW
Frontier Investment Corp
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
FHLTU
Future Health ESG Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
FHLTW
Future Health ESG Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
50.2
Composite
|
$40.50
|
Growth
55.6
|
|
Shell Companies
|
-
|
23.2
Composite
|
$12.00
|
Health
41.5
|
|
Shell Companies
|
-
|
28.4
Composite
|
$12.02
|
Valuation
55.9
|
|
Shell Companies
|
-
|
23.2
Composite
|
$0.03
|
Health
41.5
|
|
GBIO
Generation Bio Co.
Biotechnology
|
-
|
52.1
Composite
|
$5.34
|
Efficiency
72.9
|
|
GNFT
GENFIT S.A.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
GOVXW
GeoVax Labs, Inc.
Biotechnology
|
-
|
44.7
Composite
|
-
|
Valuation
100.0
|
|
Shell Companies
|
-
|
57.1
Composite
|
$9.94
|
Profitability
62.9
|
|
Shell Companies
|
-
|
42.0
Composite
|
$0.00
|
Health
73.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.50
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$10.82
|
No pillar score
-
|
|
Shell Companies
|
-
|
51.6
Composite
|
$11.00
|
Valuation
100.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
$6.50
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$6.56
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.04
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
GLYC
GlycoMimetics, Inc.
Biotechnology
|
-
|
46.4
Composite
|
-
|
Health
69.0
|
|
Shell Companies
|
-
|
28.4
Composite
|
$10.72
|
Profitability
41.0
|
|
Shell Companies
|
-
|
40.5
Composite
|
$0.01
|
Profitability
58.5
|
|
Shell Companies
|
-
|
44.3
Composite
|
$11.02
|
Profitability
53.5
|
|
Shell Companies
|
-
|
44.3
Composite
|
$0.10
|
Profitability
53.5
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$15.52
|
No pillar score
-
|
|
HONDU
HCM II Acquisition Corp.
Shell Companies
|
-
|
43.6
Composite
|
-
|
Valuation
100.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$13.90
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
41.9
Composite
|
$4.65
|
Growth
57.5
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.18
|
No pillar score
-
|
|
Shell Companies
|
-
|
46.0
Composite
|
-
|
Profitability
55.9
|
|
HHGCU
HHG Capital Corporation
Shell Companies
|
-
|
46.0
Composite
|
-
|
Profitability
55.9
|
|
Shell Companies
|
-
|
48.0
Composite
|
-
|
Profitability
57.5
|
|
HLVX
HilleVax, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
25.5
Composite
|
$0.04
|
Profitability
47.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
36.6
Composite
|
$5.00
|
Health
49.1
|
|
Shell Companies
|
-
|
24.1
Composite
|
-
|
Profitability
32.4
|
|
Shell Companies
|
-
|
22.1
Composite
|
-
|
Health
27.7
|
|
HUMAW
Humacyte, Inc.
Biotechnology
|
-
|
44.0
Composite
|
$0.01
|
Growth
55.5
|
|
IMAB
I-MAB
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
IKNA
Ikena Oncology, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
IMTXW
Immatics N.V.
Biotechnology
|
-
|
53.3
Composite
|
-
|
Valuation
100.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
38.9
Composite
|
-
|
Profitability
58.3
|
|
Shell Companies
|
-
|
40.6
Composite
|
$2.31
|
Profitability
58.3
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
INZY
Inozyme Pharma, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
41.5
Composite
|
$11.49
|
Health
54.1
|
|
Shell Companies
|
-
|
41.5
Composite
|
$0.05
|
Health
54.1
|
|
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.86
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.02
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$9.50
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$5.51
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.10
|
No pillar score
-
|
|
ISRLU
Israel Acquisitions Corp
Shell Companies
|
-
|
44.9
Composite
|
$11.02
|
Efficiency
84.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
IXQWF
IX Acquisition Corp.
Shell Companies
|
-
|
31.9
Composite
|
-
|
Profitability
43.2
|
|
Biotechnology
|
-
|
53.9
Composite
|
$0.00
|
Valuation
100.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
JVSAU
JVSPAC Acquisition Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
30.0
Composite
|
$11.99
|
Health
37.8
|
|
Shell Companies
|
-
|
30.0
Composite
|
$0.02
|
Health
37.8
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
53.6
Composite
|
$0.10
|
Valuation
100.0
|
|
KRON
Kronos Bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
59.9
Composite
|
$0.63
|
Profitability
71.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
LEXXW
Lexaria Bioscience Corp.
Biotechnology
|
-
|
46.6
Composite
|
$0.00
|
Valuation
100.0
|
|
Biotechnology
|
-
|
61.1
Composite
|
$0.02
|
Valuation
100.0
|
|
Shell Companies
|
-
|
44.4
Composite
|
$36.05
|
Profitability
59.4
|
|
Shell Companies
|
-
|
64.0
Composite
|
$30.28
|
Valuation
100.0
|
|
Shell Companies
|
-
|
44.2
Composite
|
-
|
Profitability
59.2
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
MRUS
Merus N.V.
Biotechnology
|
-
|
54.6
Composite
|
$90.00
|
Valuation
61.3
|
|
Shell Companies
|
-
|
32.5
Composite
|
$0.02
|
Health
41.4
|
|
Shell Companies
|
-
|
24.6
Composite
|
$11.89
|
Health
35.4
|
|
Shell Companies
|
-
|
24.6
Composite
|
$11.50
|
Health
35.4
|
|
Biotechnology
|
-
|
49.3
Composite
|
$0.01
|
Profitability
65.7
|
|
MCAAU
Mountain
Shell Companies
|
-
|
42.0
Composite
|
-
|
Health
53.2
|
|
MCAA
Mountain
Shell Companies
|
-
|
42.0
Composite
|
-
|
Health
53.2
|
|
Shell Companies
|
-
|
42.0
Composite
|
-
|
Health
53.2
|
|
Shell Companies
|
-
|
27.7
Composite
|
$10.92
|
Profitability
36.0
|
|
MURA
Mural Oncology plc
Biotechnology
|
-
|
55.9
Composite
|
-
|
Profitability
67.0
|
|
Shell Companies
|
-
|
41.9
Composite
|
-
|
Health
61.3
|
|
Shell Companies
|
-
|
41.9
Composite
|
-
|
Health
61.3
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
41.5
Composite
|
$0.01
|
Valuation
100.0
|
|
Shell Companies
|
-
|
25.7
Composite
|
-
|
Health
38.0
|
|
Shell Companies
|
-
|
25.7
Composite
|
-
|
Health
38.0
|
|
Shell Companies
|
-
|
27.1
Composite
|
-
|
Health
38.0
|
|
Biotechnology
|
-
|
52.7
Composite
|
$8.32
|
Profitability
61.6
|
|
Shell Companies
|
-
|
43.6
Composite
|
$0.08
|
Health
51.6
|
|
Shell Companies
|
-
|
46.4
Composite
|
$12.99
|
Health
54.7
|
|
Shell Companies
|
-
|
55.3
Composite
|
$11.16
|
Growth
58.3
|
|
Biotechnology
|
-
|
44.9
Composite
|
$0.03
|
Valuation
100.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
NLSPW
NLS Pharmaceutics Ltd.
Biotechnology
|
-
|
0.0
Composite
|
$0.02
|
No pillar score
-
|
|
Biotechnology
|
-
|
41.3
Composite
|
$0.01
|
Valuation
100.0
|
|
NTRBW
Nutriband Inc. Warrant
Biotechnology
|
-
|
53.0
Composite
|
$0.55
|
Profitability
72.5
|
|
Shell Companies
|
-
|
41.4
Composite
|
$12.07
|
Health
49.5
|
|
Shell Companies
|
-
|
50.6
Composite
|
$10.80
|
Health
59.8
|
|
Biotechnology
|
-
|
0.0
Composite
|
$0.14
|
No pillar score
-
|
|
OABIW
OmniAb, Inc.
Biotechnology
|
-
|
64.8
Composite
|
$0.39
|
Valuation
100.0
|
|
Biotechnology
|
-
|
50.6
Composite
|
-
|
Profitability
60.3
|
|
OPT
Opthea Limited
Biotechnology
|
-
|
35.0
Composite
|
-
|
Efficiency
62.9
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
49.1
Composite
|
$0.00
|
Growth
57.9
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
44.6
Composite
|
-
|
Valuation
100.0
|
|
Shell Companies
|
-
|
29.5
Composite
|
-
|
Health
33.3
|
|
Shell Companies
|
-
|
27.2
Composite
|
-
|
Efficiency
79.3
|
|
Shell Companies
|
-
|
27.2
Composite
|
$12.00
|
Efficiency
79.3
|
|
Shell Companies
|
-
|
27.2
Composite
|
$11.32
|
Efficiency
79.3
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
47.5
Composite
|
$11.06
|
Growth
58.5
|
|
Shell Companies
|
-
|
34.9
Composite
|
$11.00
|
Efficiency
46.2
|
|
PRTG
Portage Biotech Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
53.5
Composite
|
$0.01
|
Profitability
73.6
|
|
Biotechnology
|
-
|
52.1
Composite
|
$0.02
|
Valuation
100.0
|
|
Shell Companies
|
-
|
46.8
Composite
|
-
|
Valuation
100.0
|
|
Shell Companies
|
-
|
41.4
Composite
|
-
|
Valuation
100.0
|
|
Shell Companies
|
-
|
31.6
Composite
|
-
|
Health
49.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
53.5
Composite
|
$12.00
|
Growth
63.4
|
|
Shell Companies
|
-
|
43.5
Composite
|
$11.31
|
Profitability
52.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
52.2
Composite
|
-
|
Profitability
74.8
|
|
Biotechnology
|
-
|
46.2
Composite
|
$0.00
|
Growth
68.0
|
|
Biotechnology
|
-
|
60.8
Composite
|
-
|
Valuation
100.0
|
|
Biotechnology
|
-
|
55.0
Composite
|
$9.90
|
Valuation
100.0
|
|
Shell Companies
|
-
|
55.2
Composite
|
$33.99
|
Profitability
64.5
|
|
RFAC
RF Acquisition Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
RFACU
RF Acquisition Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
43.8
Composite
|
$43.90
|
Profitability
55.4
|
|
Shell Companies
|
-
|
37.9
Composite
|
$10.80
|
Profitability
45.3
|
|
Biotechnology
|
-
|
58.2
Composite
|
$0.00
|
Valuation
100.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
44.1
Composite
|
$0.08
|
Valuation
83.4
|
|
SIMAU
SIM Acquisition Corp I
Shell Companies
|
-
|
46.4
Composite
|
$11.11
|
Profitability
55.3
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
36.1
Composite
|
$11.93
|
Health
53.1
|
|
Shell Companies
|
-
|
36.9
Composite
|
$0.83
|
Health
53.1
|
|
Shell Companies
|
-
|
33.8
Composite
|
-
|
Efficiency
41.9
|
|
Shell Companies
|
-
|
34.9
Composite
|
$12.70
|
Efficiency
41.9
|
|
Shell Companies
|
-
|
36.6
Composite
|
-
|
Profitability
44.2
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
52.3
Composite
|
$10.99
|
Profitability
60.1
|
|
SRZNW
Surrozen, Inc. Warrant
Biotechnology
|
-
|
52.3
Composite
|
$0.02
|
Profitability
76.0
|
|
Shell Companies
|
-
|
42.1
Composite
|
$10.86
|
Profitability
47.2
|
|
Biotechnology
|
-
|
0.0
Composite
|
$0.50
|
No pillar score
-
|
|
Biotechnology
|
-
|
56.9
Composite
|
$0.01
|
Valuation
100.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
$3.39
|
No pillar score
-
|
|
Biotechnology
|
-
|
45.0
Composite
|
-
|
Valuation
98.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
TRML
Tourmaline Bio, Inc.
Biotechnology
|
-
|
47.3
Composite
|
-
|
Health
69.6
|
|
Shell Companies
|
-
|
54.4
Composite
|
$11.48
|
Profitability
67.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
VMCAW
Valuence Merger Corp. I
Shell Companies
|
-
|
0.0
Composite
|
$0.05
|
No pillar score
-
|
|
VMCAU
Valuence Merger Corp. I
Shell Companies
|
-
|
45.9
Composite
|
$11.37
|
Profitability
59.7
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.74
|
No pillar score
-
|
|
VRNA
Verona Pharma plc
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
44.0
Composite
|
$11.21
|
Growth
72.5
|
|
Biotechnology
|
-
|
40.3
Composite
|
-
|
Profitability
48.2
|
|
Shell Companies
|
-
|
43.2
Composite
|
$14.50
|
Profitability
54.2
|
|
Shell Companies
|
-
|
28.0
Composite
|
$10.00
|
Profitability
41.0
|
|
Shell Companies
|
-
|
31.3
Composite
|
$7.50
|
Profitability
47.9
|
|
Shell Companies
|
-
|
59.7
Composite
|
$28.38
|
Growth
84.8
|
|
Shell Companies
|
-
|
25.6
Composite
|
$11.32
|
Profitability
35.0
|
|
Shell Companies
|
-
|
26.8
Composite
|
-
|
Profitability
35.6
|
|
Biotechnology
|
-
|
70.0
Composite
|
$24.98
|
Profitability
78.6
|
|
Biotechnology
|
-
|
68.7
Composite
|
$25.00
|
Profitability
78.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
37.2
Composite
|
$11.15
|
Health
44.4
|
|
Shell Companies
|
-
|
22.6
Composite
|
$13.99
|
Profitability
42.3
|
|
Shell Companies
|
-
|
27.6
Composite
|
$2.00
|
Profitability
52.8
|
|
Shell Companies
|
-
|
22.6
Composite
|
-
|
Profitability
42.3
|
Try a broader company name, ticker, sector, or industry keyword.
This framework combines industry-specific diagnostics, moat context, and peer benchmarks so each signal stays grounded in how this business model actually compounds.
We group pre-commercial biotech and similarly early-stage businesses into a separate framework because revenue, margins, and near-term profitability are often the wrong lens. The money-flow engine starts with cash on hand, then follows operating expense, R&D intensity, operating cash burn, financing inflows, and estimated runway.
That same logic carries into the broader StatsAlpha(TM) framework. The trade-off ledger for pre-revenue biotech is intentionally sparse in the current implementation: profitability is disabled, safety focuses on liquidity and cash position, and the code explicitly flags the need for future runway and burn-specific calculators. That is a feature, not a gap in judgment. The framework avoids pretending these businesses can be compared like mature cash generators.
On the moat and valuation side, biotech currently inherits broader corporate tools where needed, but the fair-value defaults also acknowledge the category's binary nature and note that a probability-of-success layer would be preferable to a smooth-growth DCF. In practice, this profile should be read as a disciplined way to track funding durability and upside optionality, not as a shortcut to certainty. This framework is for informational purposes only, not investment advice.
Each layer answers a different question: where value is created, what protects it, and how execution compares with the rest of the coverage set.
Benchmarks and narrative cues are meant to clarify what the framework is seeing in the data. They are not investment advice.
Coverage starts with the companies that actually operate inside this business model, so peer comparisons stay relevant instead of generic.
The Biotech / Pre-Revenue layer isolates the cash-flow mechanics, capital demands, and operating risk that matter most for this industry.
We then layer in Corporate Default, pillar ranges, and peer leaders to show what strong execution looks like relative to the broader cohort.